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SUMMARY
Melanoma cells are transformed melanocytes which usually retain their receptors for 
alpha-melanocyte-stimulating hormone (a-M SH). MSH promotes melanogenesis and 
melanin dispersion in pigment cells. The selective affinity of MSH for its receptor may 
allow site-specific delivery of probes or drugs to melanoma during its diagnosis and 
treatment This thesis concerns the interaction and synthesis of such compounds with B16 
murine melanoma cells.
In vitro studies with the a-M SH analogue [,25I-Tyr2,Nle4,D-Phe7]-a-M SH (125I-NLDP) 
identified an average of 18,040 receptors per B16 melanoma cell. Saturation binding 
isotherms revealed a specific affinity of the tracer for the a-M SH  receptor (a-MSH-R) 
with a dissociation constant (Kd) of 4.76xl0*10 ML The fluorescent label ((chlorotriazin-2- 
yl)amino)fluorescein (CTAF), 125iodine (125I)» biotin (Bi), 4-(l-Azi-2,2,2,-
trifluoroethyl)benzoate (ATB) labels, and methotrexate (MTX) were attached to NLDP. 
Targeting of these and other probes to the a-M SH-R was determined with competition 
assays against 12SI-NLDP. All melanotropin conjugates studied, except for a streptavidin- 
gold-Bi-,25I-NLDP complex, specifically interacted with the a-M SH-R of B16 melanoma 
cells.
Following receptor binding, receptor-mediated transport of 125I-NLDP into the melanoma 
cytosol was observed at 372C. This suggests the internalisation of a-MSH-R-agonist 
complexes during receptor activation and subsequent cellular response. All probes tested, 
and MTX-NLDP, were agonistic to the a-MSH-R. The probes show promise for : 1) 
imaging of melanoma during its diagnosis; 2) imaging of the MSH-R-ligand complex and
its intracellular pathway; 3) site-selective drug delivery during treatment against 
melanoma; and 4) the extraction and purification of the MSH-R from B16 melanoma 
plasma membranes.
In this study, a-M SH and NUDP inhibited cell growth of B16 murine melanoma cells in 
vitro. The effect was time, concentration and cell density dependent Pulse dosing of the 
cells with NLDP for 30 minutes/day had no effect on cell proliferation. During treatment 
of melanoma, MSH has the dual advantage of: 1) targeting probes and drugs to, and 
possibly within, melanoma; and 2) retarding melanoma cell growth. The application of 
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Alpha-melanocyte-stimulating hormone (a-M SH) is best known for its promotion of 
melanogenesis and pigment dispersion in melanocytes and their transformed counterparts, 
melanoma (154). Most human melanoma express MSH receptors (53, 71, 160). The 
hormone stimulates melanogenesis in pigment cells via a Gs protein coupled receptor 
located in the cellular plasma membrane. Receptor activation sets in motion a number of 
co-ordinated intracellular signalling pathways related to melanin biosynthesis and 
migration. These intracellular mechanisms also regulate the cell morphology and 
proliferation of pigment cells (99, 138).
1.2. DISTRIBUTION OF MELANOTROPINS
The various physiological effects of a-M SH are well documented in the literature (52). 
These reports are focused mainly on the Central Nervous System (CNS) and on 
pigmentation in animal models. In most animals, the primary site of biosynthesis of a- 
MSH is the intermediate lobe of the pituitary pars intermedia (P.I.). Here, it and other 
melanotropic peptides are secreted by large polygonal MSH-producing type 1 cells. These 
cells are rich in mitochondria, contain well developed rough endoplasmic reticulum 
(RER), golgi apparatus and an abundance of secretory vesicles of various densities (168).
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In the P.I. of mammals, a -  and p-MSH immunoreactivity is present in cells which also 
contain corticotrophin (ACTH, 52). This is expected as all three peptides originate from a 
common precursor (POMC, 128). Type 1 cells are found with smaller strictly ACTH 
producing type 2 cells, and astrocyte-like glial cells (type 3) which form a loose meshwork 
in the P.I.. These type 3 cells show no signs of secretory function but display high 
oxidative enzyme activity (90).
Cells containing MSH are also present in the zone intermedia and in the pars distalis 
(P.D.) of human pituitaries (188). Human pituitaries produce pro-y-MSH peptides (174) 
and (des)acetylated-a-MSH (12, 55, 180). Immuno-gold techniques against y -  and a -  
MSH confirmed their localisation in mature secretory vesicles of melanotrophs (169). 
Desacetyl-a-MSH and a-M SH are the most common melanotropins found in adult man.
Although a-M SH is unevenly distributed in the human brain, it is associated with a 
number of regions. Melanotropic peptides are transported from the pituitary to the 
hypothalamus. The highest concentration of MSH is found in the hypothalamus (4,11). 
They are also associated with a number of regions of the CNS. Certain neurones of the 
human hypothalamus also produce (3-MSH (13). In man, more than a third of the a -  
MSH is contained within synaptosomes, less than a third is associated with sub-cellular 
particles, and very low amounts occur in the cytosol (135).
Specific receptors for a-M SH are widely distributed in rodents (175). A potent MSH 
tracer (125I-NLDP) was injected into rats to determine melanotropin uptake in tissue. 
Binding of the tracer was found in a number of glandular organs, adipose tissues, bladder, 
duodenum, skin, spleen, and hypothalamus. Other studies have shown an initial high 
uptake of the tracer by the kidneys, liver, spleen, adrenals, and tumour after injection into 
mice bearing melanoma (52). Dupont, A. et al (47) observed a more localised distribution
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of MSH. He observed a veiy high uptake of 125I-a-MSH into the rat pineal gland relative 
to other organs, 5 minutes after an intrajugular injection.
1.3. REGULATION OF MELANOTROPINS
MSH release from the CNS is controlled by MSH releasing factors (MRF) and release- 
inhibiting factors (MIF). Some mammalian MIFs are dopamine, y-aminobutyric acid 
(GABA), enkephalin, melatonin, serotonin, and somatostatin. Some MRFs are 
(nor)adrenaline, vasopressin and corticotrophin releasing factor (CRF), and opiates (3,96, 
199). Both gonadal steroids oestrogen and progesterone regulate MSH release via 
hypothalamic MIF and MRFs in female rats (182). Stress stimuli cause a 2-8 fold increase 
of a -  and y-MSH in rat plasma via MRF regulation (181)
The secretion of a-M SH is subject to diurnal and annual variations. Humans have 
elevated a-M SH levels in the afternoon and evening (72), while the highest [3-MSH 
values are observed first thing in the morning with lowest values after retiring (173). Our 
basal |3-MSH content is higher in the winter than in summer (189).
1.4. EFFECTS OF MELANOTROPINS
The effects of melanotropins on the CNS are well documented (52). Alpha-MSH 
facilitates adaptive behaviour and improves memory in man. This occurs with the 
increased efficiency of impulse transmission across existing synapses, and the growth and 
formation of new synapses. This melanotropin induced neural plasticity also affects social,
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sexual and grooming behaviour, nerve regeneration, and brain development in 
experimental animals.
Alpha-MSH stimulates sebum secretion in the skin of rats. It also regulates prolactin, 
lutenizing hormone (LH), growth hormone (hGH), aldosterone, and ACTH in glandular 
organs. It increases heart rate, causes permeability changes in the eye, natriuresis in the 
kidneys, and lipolysis in fat cells (52). It also reduces inflammation and lowers high body 
temperature caused by stimulation of the immune system by modulating immuno- and 
neuroendocrine effects of interleukin-1 (41,114,147).
1.5. EFFECTS OF MELANOTROPINS ON PIGMENT CELLS
1.5.1. INTRODUCTION
Pigmentation of animals is very complex with regulation-effect systems varying between 
species. Descriptions of pigment cell responses to melanotropins will apply primarily to 
melanocytes and melanoma of mammals with some reference to melanophore systems.
1.5.2. THE HUMAN EPIDERMAL MELANIN UNIT
Melanotropins are best known for eliciting a morphological change in melanocytes, 
pigment cells of the human skin. Melanocytes are derived from the neural crest from
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where they migrate as undifferentiated melanoblasts into the dermis. They later invade the 
epidermis and differentiate into melanocytes (145). The function of melanocytes in 
mammalian skin is to form and maintain dendrites, to synthesise melanosomes, and to 
secrete them into adjacent keradnocytes. Keratinocytes will phagocydse single or groups 
of melanosomes, either free or still housed in melanocyte dendrites. The melanosomes are 
then broken-down by lysosomes, and the encased melanin is dispersed in the keratinocytes 
(56). The movement of melanosomes from the perkaryon to the dendritic processes of the 
melanocyte is accomplished with the energy-dependent co-ordination of microtubules and 
filaments (106, 151). Each melanocyte together with 36 keratinocytes constitutes the 
epidermal melanin unit (56).
15.3. BIOMECHANISMS OF MELANIN SYNTHESIS
Melanin is formed in melanosomes of pigment cells following an increase of tyrosinase, the 
rate-limiting enzyme of melanogenesis. Tyrosinase synthesis occurs in membrane bound 
poly-ribosomes of the rough endoplasmic reticulum (RER) and is regulated by MSH and 
L-Dopa (164). Glycosylation and processing of the enzyme is carried out in Golgi 
associated endoplasmic reticulum of the lysosome (GERL). The tubular end portions of 
the GERL bud off to form coated vesicles and are transported to premelanosomes. Here 
melanin biosynthesis takes place to form mature melanosomes containing melanin (125).
A summary of the Raper-Mason melanin biochemical pathway is : 1) tyrosinase catalyses 
the hydroxylation of tyrosine to dopa and ; 2) the oxidation of dopa to dopaquinone; 3) 
dopaquinone undergoes non-enzymatic cyclisation; 4) oxidation; and 5) aromatisation into 
5,6 dihydroxyindoles; 6) which undergo oxidative polymerisation to form melanin (170).
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Pigmentation of the human skin is categorised as either constitutive (intrinsic) or 
facultative (inducible). Constitutive skin colour is the genetically determined level of 
cutaneous melanin pigmentation in the absence of direct or indirect influences. Facultative 
skin colour is the increase in melanin pigmentation above the constitutive level. Skin 
coloration is determined by : 1) the total number of melanosomes present within the 
epidermal melanin unit; 2) the rate of melanogenesis within the melanocytes and; 3) the 
rate of melanosomal transport within the keratinocyte population. Four factors determine 
melanocyte form and function : 1) genotype of the melanoblast; 2) genotype of the 
environmental cells; 3) the environmental history of the melanocyte and ; 4) the 
characteristics of the differentiated environmental cells. Racial differences in pigmentation 
are not due to differences in the number of melanocytes, but to differences in the cellular 
area occupied by the RER, the development of the golgi zone, and the maturation of the 
melanosomes (146).
1.5.4. EFFECTS OF MELANOTROPINS ON MELANOCYTES
Functional receptors for melanotropins have been identified in mouse melanocytes (44). 
Melanocytes can be induced to develop dendrites and form melanin by treatment with 
MSH, dibutyryl cyclic adenosine monophosphate (db-cAMP), or MSH in combination 
with theophylline (85,91,98). Together, theophylline and MSH caused the differentiation 
of melanocyte primary cultures in serum-free media (initiation of melanin synthesis in 
melanoblasts; 85). Although alone, a-M SH failed to induce differentiation of cultured 
melanocytes in the absence of keratinocytes. Alpha-MSH had no effect in serum-free 
organ culture models for mouse skin (86).
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The effect of a-M SH on melanocyte growth is also controversial. Stimulation of human 
melanocyte growth in culture by a-M SH and db-cAMP has been reported (83, 98). But 
other researchers did not observe a change in the rate of melanocyte growth when the cells 
were exposed to MSH in serum or serum-free media (54,81,86,198).
In vivo reports document a more consistent response of melanocytes to MSH. 
Melanotropins induced differentiation in the epidermis of new-born mouse skin. Both a -  
and p-MSH caused skin darkening in man (107). Facultative melanogenesis in human skin 
was observed 10 hours after intra-muscular injections of crude MSH (104). The 
transdermal drug delivery of MSH in vitro and in vivo had no toxic side effects on humans 
(45).
1.6. EFFECT OF MELANOTROPINS ON MELANOMA
1.6.1. INTRODUCTION
The effect of melanotropins on melanoma has been studied more extensively on melanoma 
than melanocytes. There have been several reports of MSH increasing pigmentation, 
cellular cAMP levels, and tyrosinase expression while inhibiting cell growth. Alpha-MSH 
also increased tyrosinase activity and melanogenesis in tumour-bearing mice (100). Other 
investigators have also observed an anti-proliferative effect of melanotropins on melanoma 
in vitro and in vivo (39, 130, 136, 195), while others found MSH to stimulate melanoma 
cell growth (27,122).
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1.6.2. INHIBITION OF MELANOMA CELL GROWTH
MSH induced inhibition of melanoma growth is usually attributed to; the build-up of toxic 
products from melanin biosynthesis, raised intracellular cAMP levels, or autocrine growth 
inhibitors (80,108,136,139,140,141, 148).
Wick (194) suggested three groups of toxic compounds related to major metabolites in the 
pigment pathway, were responsible for auto-toxicity of cells during melanogenesis. These 
were tyrosine, levodopa, and 5,6-dihydroxyindole. Tyrosine levels were elevated 
sufficiently to cause toxicity in pigment producing cells relative to their non-pigmenting 
counterparts (136, 137). An a-MSH induced increase in intracellular tyrosine was found 
to correspond with a reduction of DNA in Cloudman S91 melanoma cells (79). Levodopa 
was also selectively toxic to pigment cells in vitro. It displayed anti-tumour activity in B16 
melanoma (191, 192, 193). The proposed mechanism for cell auto-toxicity by these 
compounds is as follows : 1) quinols present in the cell are converted to quinones by 
MSH-induced elevated levels of tyrosinase; 2) quinones then inactivate DNA polymerase 
which is sensitive to oxidising conditions; 3) the lack of active DNA polymerase inhibits 
cell growth. Dihydroxyindole can also be cytotoxic to melanoma cells in vitro but possibly 
via a different route (139). This compound is an extremely reactive nucleophile and 
electrophile. Its cytotoxicity may be related to the generation of superoxide radicals. The 
free radicals could then cause cell death. The chronic low amounts of superoxide radicals 
produced during melanogenesis might explain why melanoma cells are inherently resistant 
to free radical chemotherapy (30).
Several investigators observed MSH related growth inhibition of melanoma to coincide 
with the accumulation of intracellular messengers rather than melanin synthesis. Agents
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(MSH) that induced dendrite formation, raised intracellular cAMP, and increased 
tyrosinase activity, also inhibited cell growth without inducing melanogenesis (163). 
Cyclic AMP appeared to follow a pathway which reduced cell proliferation independent 
from melanin synthesis. Thus, cell inhibition was not caused to by melanogenic toxic by­
products. Slominiski (164) claimed the a-M SH growth inhibition seen in amelanotic cells 
without the involvement of melanogenesis or tyrosinase expression, was due to a rapid (a 
few seconds) 'outburst' in cytosolic myo-inositol phosphates. The a-M SH  activated 
second messenger, protein kinase C (PKC) has also been observed to inhibit B16 mouse 
melanoma cell proliferation (28, 73). Pawelek (140) suggested MSH inhibited melanoma 
proliferation due to raised level of both cellular cAMP and cytotoxic by products from 
melanin biosynthesis.
Melanoma are also suggested to regulate their own growth with autocrine growth- 
inhibiting compounds. Bogdahn et al (21) has isolated three autocrine-secreted tumour 
cell growth-inhibiting agents (MLAt, ML\n, and MIAm) from a malignant melanoma cell 
line. They were observed to inhibit proliferation of melanoma and neuroectodermal 
tumors. Normal fibroblasts were uneffected by the MIAs. Rodeck (148) has also described 
the inhibition of melanoma growth by a melanoma secreted transforming growth factor 
(TGF-p). Bioactive TGF-p may represent a physiological growth inhibitor of melanoma.
1.6.3. STIMULATION OF MELANOMA CELL GROWTH
Alpha-MSH has been reported to stimulate melanoma growth : 1) in soft agar cultures 
with low or normal tyrosinase content in the medium (122); and 2) in vitro using mouse 
melanoma tumours inoculated from cultures raised in soft agar bilayers with, or without,
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serum (27). Most of these authors suggest a form of melanoma self-incitement or 
endogenous growth hormone caused an increase in melanoma growth (8, 118). It is 
produced and secreted into the surrounding environment by the cells to cause a positive 
feedback system (205).
Several self-regulatory human melanoma growth factors have been identified by the 
secretion of their RNA transcripts into the cell supernatant These were melanoma growth 
stimulatory activity (MGSA), basic fibroblast growth factor (bFGF), platelet-derived 
growth factor (PDGF-a, PDGF-p), transforming growth factor (TGF-P 1, TGF-a), and 
interleukin (IL -la, IL-1P; 25, 143). The two factors bFGF and MGSA contributed to 
autocrine growth stimulation of melanoma. These agents were also expressed by 
melanocytes (148). In M2R and B16-F1 mouse melanoma cells, PKC was found to 
stimulate cell growth rather than reduce it (67,119).
1.7. MECHANISMS FOR THE ACTION OF MELANOTROPINS 
ON MELANOMA CELLS
1.7.1. INTRODUCTION
In man, MSH is cleaved from its pro-opiomelanocortin (POMC) precursor and travels 
from the zona intermedia and PD into the hypothalamus. It is then secreted into the blood 
stream where it has pleiotropic effects throughout the body. It regulates the 
differentiation, growth, and melanogenesis of pigment cells and their transformed 
counterparts, melanoma. This is accomplished by binding to specific receptors on the cell 
plasma membrane. Receptor occupation triggers several signal transduction mechanisms
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and the possible internalisation of the ligand-receptor complex. The intracellular pathway 
of the ligand-receptor complex is unknown although data suggests lysosomal degradation 
of the ligand. It is not known if the receptor is recycled or degraded along with the ligand. 
Intracellular signals are terminated with the removal of the hormone from the cell surface 
receptors. Uncoupling of the ligand from the MSH-receptor (MSH-R) could be due to one 
or a combination of events, ligand internalisation, inactivation (biodegradation), or 
dissociation from the receptor.
1.7.2. STRUCTURE-FUNCTION ASPECTS OF MELANOTROPINS FOR THEIR 
RECEPTORS
Alpha-MSH was first isolated from porcine pituitary in 1955 by Lemer and Lee (105). Its 
primary structure was subsequently determined by Harris and Lemer (78). The identical 
hormone was found in ovine, equine, and macaque pituitaries (69). The complete 13 
amino acid sequence of a-M SH was identical with the N-terminal tridecapeptide 
sequence of corticotrophin (ACTH). The seven peptide ’core' of a-M SH was also found 
in (3- and y-MSH (154). The amino acid sequence of £-MSH corresponds to (3- 
lipotropin (p-LPH) at sequence 41-58 (52). The homology of these 5 peptides suggest a 
common pro-opiomelanocortin precursor (POMC, 128).
The 31 kDa POMC has since been isolated from man, rat, and ox (35, 46, 129). The 
peptides are biologically active once cleaved from the POMC by glycosylation, amidation, 
or acetylation. A common precursor for the melanotropins, ACTH, lipotropin, and 
endorphin explains the pleiotropic nature of MSH. The close genetic relationship of these 
peptides would cause similarities in their function and co-localisation. The pleiotropic
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effects are augmented by the biotransformation of melanotropins by metabolising enzymes 
to other substances such as opioids, substance P, and other neuropeptides (75,196).
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Figure 1.1. The structures of human ACTH and a-MSH showing their homology. Taken 
from Shizumi (154).
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Figure 1.2. The structure of the ACTH-p-LPH precursor showing the homology of a-, p-, 
and y-MSH. Taken from Shizumi (154).
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Figure 1.3. Schematic representation of the gene, mRNA and protein structure of bovine 
pro-opiomelanocortin (POMC), the precursor for adrenocorticotropin (ACTH), lipotropin 
(LHP), melanotropins (MSHs), endorphin (EP), adrenal growth factor (AGF, pro-y- 
MSH), adrenal mitogenic hormone (AMH), and joining peptide (JP). Taken from Eberle 
(52).
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Structuie-activity relationships of melanotropins and related peptides have been well 
studied in amphibian (Rana pipiens and Xenopus laevis tadpoles) and reptiles (Anolis 
Carolines) melanophores. They have also been examined in the Qoudman S91 and B16 
mouse melanoma cellular models. The quantitative induction of melanogenesis by MSH 
has been performed with B16 melanoma monolayers in melanin assays (155).
Alpha-MSH was the most potent naturally occurring peptide in these experimental 
systems. (3-MSH was 1/20 to l/4th as potent as a-M SH on a weight basis (69). Gamma- 
MSH only induced tyrosinase activity and dendrite formation in mammalian melanoma 
cells at very high concentrations (10}iM, 165). Gamma^MSH displayed 0.075% the 
activity of a-M SH in melanophore assays (113).
Eberle (52) has found chain elongation or shortening of the natural MSH-tridecapeptide 
sequence decreased biological activity in all bioassays. The shortest peptide to stimulate 
pigment-dispersion in the frog skin was the 6-9 fragment -His6-Phe7-Arg8-Tip9-. This is 
regarded as the 'core' sequence for melanotropic activity. The shortest peptide sequence 
with measurable activity in melanoma cells was the 5-10 fragment -Glu5-His6-Phe7-Arg8- 
Trp9-Gly10-. Eberle (52) claimed the different responses are due to the higher sensitivity of 
melanophore versus melanoma assays.
Further studies (52) depicted two separate regions within the a-M SH sequence 
containing MSH bioactivity. Message 1 was the central sequence 4-8 -Me^-Glu^His6- 
Phe7-Arg8- which stimulated bioactivation. Message 2 was the C-terminal 10-13 -Gly10- 
Lysn -Pro12-Val13-NH2 sequence which potentiated the effect The -Phe7-Arg8- and - 
Lysn -Pro12- regions were particularly important for binding and stimulation of MSH 
receptors. No clear distinction could be made between the binding and biological 
stimulation within the MSH peptide.
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When the size or lipophilicity of the peptide was increased, its activity generally dropped 
by a factor of 2-10 fold. Attachment of MSH to polyethylene glycol (PEG-5000) at its N- 
terminal reduced its biological activity to 1% its original value. Blockage of a-M SH at the 
N-terminus with bulky protecting groups reduced the activity by a factor of 400 (52). 
Generally, conjugates retained a high degree of biological activity when they were 
attached to the protein via its N-terminus. The C-terminal of a-M SH was stricter than the 
N-terminaL A basic side-chain at position 11 and a conformational stabilising element at 
position 12 were necessary for biological stimulation. The presence of a residue at position 
13 was also essential for biological activity (50).
Oxidation of the Met4 resulted in a 20-100 fold loss in activity and reduced binding to 
melanoma cells (158). This may represent a pathway for the inactivation of the hormone in 
vivo. Alpha-MSH labelled at its tyrosine2 residue with 125iodine using an equimolar 
chloramine T procedure, produced a monoiodinated tracer with 50% the biological 
activity of unlabelled a-M SH (49). Nle4-containing MSH peptides were not oxidised at 
position 4, and therefore were more resistant to chloramine T oxidation during iodination 
and retained their biological and binding properties. Replacement of Met4 by the isosteric 
residue of norleucine increased the tyrosinase activity of a-M SH by 62.5% in Qoudman 
melanoma assays.
In all pigment cell bioassays [Nle4J)-Phe7]-a-M SH (NLDP) was more active than a -  
MSH. It was 8-120 fold more potent in Qoudman melanoma cells and 12-fold more active 
in B16 melanoma assays. It was the most potent a-M SH derivative available other than 
the homologous [Nle4,D-Phe7, Trp(Naps)9]-a-M SH photoaffinity label (52). NLDP 
expressed tyrosinase-stimulating activity for up to 6 days after removal from the cell 
medium (119). NLDP appeared to almost irreversibly bind to the MSH-R with
14
conformational properties which stabilised the interaction. The D-Phe residue in position 7 
might protect the peptide from chemical degradation during in vitro and in vivo 
conditions. This would explain the higher potency observed with [D-Phe7]-a-M SH 
analogues relative to the [L-Phe7]-hormone (52).
Dissociation constants (Kd) for a-M SH, [Nle4]-a-M SH, and [Nle4JD-Phe7}-a-M SH 
were obtained from competition binding assays on B16 mouse melanoma suspensions. 
They were 1.9, 1.8, and 0.32xl0-9 M, respectively (158). The exchange of L-Phe7 for D- 
Phe7 in [Nle4]-a-M SH caused a 6 fold increase in the affinity of the peptide for B16 
receptors. The three analogues were monoiodinated at the Tyr2 residue and compared in 
binding and bioassays (53). Alpha-MSH was iodinated using the enzymobeads procedure 
(Immunobeads, Bio Rad Inc.). This protocol gently iodinated the peptide without 
oxidising the Met group and thus, preserving its biological and binding activities. All three 
radio-ligands displayed similar melanotropic activities to those observed with the 
unlabelled analogues. [Tyr 125(I)2]-a-M SH was 0.8, {Tyr 125(I)2, Nle4]-a-M SH was 0.4, 
and [Tyr 125(I)2, Nle4, D-Phe7]-a-M SH was 10.5 fold more potent than unlabelled a -  
MSH in B16 melanin dispersion assays. However in human DIO melanoma cells the 
[Nle4]-a-M SH tracer led to a high degree of non-specific binding (53). Due to its : 1) 
resistance to degradation, and/or dissociation from the MSH receptor, 2) strong biological 
activity before and after radio-labelling; and 3) low non-specific background labelling; 
NLDP is a suitable melanotropin for targeting of the MSH-R for studies of interactions of 
melanotropins with the MSH-R.
At present, there are no reports describing a potent a-M SH antagonist which binds to the 
MSH-R without eliciting a biological response from melanoma. Derivatives of Ac-Nle4- 
Asp5-His6-D-Phe7-Arg8-Trp9-Lys10-NH2 were tested on melanophores for their potential 
as a-M SH antagonists. However, several modifications in the amino acid sequence of the
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peptide resulted in a complete loss of antagonistic activity and a recovery of very weak 
agonistic action (2).
1.7.3. BINDING OF MELANOTROPINS TO SPECIFIC RECEPTORS OF 
MELANOMA
Specific binding of melanotropins and their analogues has been well documented for 
mouse and human melanoma. It has been demonstrated with murine and human cell lines 
in vitro or with tumours raised in mice. Receptor auto-radiography of a-M SH receptors 
is a quantitative method for assessing melanoma distribution in tissues.
Binding of ligands to the MSH-R was dependent on the concentration of extra cellular 
calcium (64, 116, 149). Calcium increased the binding affinity of [3-MSH for its receptor 
by a factor of 20 (63). Calmodulin inhibitors inhibited ligand binding to the receptor 
indicating regulation by a calmodulin-related calcium-binding protein (66). It is not known 
if the calcium sensitivity of the MSH-R was mediated by a separate calcium-binding 
protein, or if it itself functioned as a hormone-operated calcium gate (149). Calcium ions 
were the most effective of a series of divalent cations in the stimulation of MSH-R 
activity. These results implicate calcium as a physiological regulator of the MSH-R (64). 
The MSH and ACTH receptors belong to a unique class of peptide hormones that 
specifically require calcium for their activity (68).
Alpha-MSH-receptors have been identified on a number of mouse melanoma lines. The 
best studied of these are the B16 and S91 Qoudman models. Out of a panel of 20 human 
lines, 13 expressed a-M SH receptors (71, 158). Saturation and competition binding 
assays have quantified binding affinities for various MSH analogues and described MSH-R
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density per cell. Dissociation constants were fairly consistent regardless of experimenter or 
subclone. Kds of a-M SH ranged from 1.31-2.6xl(>9 M in B16 and Cloudman melanoma 
(158,176) with more variability in human lines at 0.92-2.2xl0-10 M (38, 53). Receptors of 
human melanoma appeared to have a 10 fold greater affinity for a-M SH  than murine 
lines. Iodination of the hormone increased its affinity for the receptor with a tracer Kd of 
0.9-1.6x1 (>9 M for 3 B16 subclones (166). Iodination of a-M SH also increased its affinity 
(28%) for receptors on human DIO melanoma cells (158). The superagonist analogue 
NLDP, had a greater affinity for the a-M SH receptor than a-MSH with a Kd which 
ranged from 2.3 to 6.3xl0-n M in human melanoma, and 5.6x1 O'11 M for its tracer in a 
B61 line (176). These results are in agreement with others citing NLDP as having a 3.12 
fold stronger affinity for its receptor than a-M SH in human DIO melanoma (158).
The association of 125I-a-M SH to 205 human melanoma cells and its analogue 125I-[Nle4]- 
a-M SH to B16 cells were similar (157, 158). Indicating that both peptides were 
recognised in the same way, by similar receptors, in both species. Dissociation of the MSH 
tracers from their receptors was time, temperature, and concentration dependent Non­
specific binding was virtually independent of time and temperature (below 25%), but not 
concentration. Panasci et al (133) found both total and non-specific binding increased 
proportionately to the ligand concentration. At 49C the amount of bound tracer did not 
increase from 4 to 24 hours. Eberle (52) observed the association of MSH-Rs with there 
ligands at 37 and 25SC to be rapid but did not reach a steady-state equilibrium. The 
specific binding decreased after reaching a maximum value at 30 minutes and 2 hours, 
respectively. Fifty percent of the bound ligand had left the cell after 35 minutes. After 4 
hours all specific binding was gone. At 252C, 50% of the receptor-bound tracer had 
dissociated from the cell by 90 minutes. At 152C, the tracer had reached a stable 
association for the cells after 3-4 hours, while at 0 -lfiC maximum binding was not reached 
until 8 hours. At 15 and 0 -lcC, 23 and 7% of the peptide was lost from the cell at 4 and 5
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hours, respectively. An increase in time and incubation temperatures accelerated the loss 
of specific binding. This loss could be due to decomposition, dissociation, or 
internalisation of the tracer (52).
Siegrist et al (157, 158) observed degradation of an a-M SH tracer after an incubation in 
B16 and DIO melanoma cell supernatant at 37CC. They attributed this to proteolytic 
enzymes secreted by the cells, into the media, has been observed with 3 human melanoma 
lines (42). Peptide degradation was significantly reduced with the addition of 1 and 0.3 
mM 1,10-phenanthroline to the binding buffer of DIO and B16 cells, respectively. 
Dissociation of the tracer was delayed from 35 minutes to 2 hours in DIO cells, and useful 
in establishing an equilibrium for specific binding of B16 cells. Recent experiments have 
shown that 1,10-phenanthroline was not necessary if the binding temperature was 15fiC or 
below, and the chemical homogeneity of the tracer was good (52). Siegrist suggested the 
use of the more degradation resistant a-MSH analogue NLDP, in future MSH binding 
studies.
1.7.4. DEMONSTRATION OF MELANOTROPIN RECEPTORS IN  VIVO
Melanotropin receptors have been characterised in experimental tumours in situ of murine 
melanoma. Frozen tissue sections of in situ tumours from mice inoculated with B16 
mouse melanoma, were subject to auto-radiography with the 125I-NLDP tracer (176). 
Specific binding was demonstrated when unlabelled melanotropins inhibited tracer binding 
to the tumours in a concentration dependent manner. Specific binding sites of a-M SH 
were distributed throughout the tumour but not associated with neighbouring non-tumour 
tissue or fibrovascular elements.
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Siegrist et al (159) also observed the high affinity of melanotropins for their receptors in 
vivo. He inoculated mice with S91 Cloudman melanoma and 4 B16 mouse melanoma 
subclones. Receptor auto-radiography of the resulting tumours displayed higher binding 
capacities and affinities than isolated cultured cells. Receptor density was greater in 
sections with 14,700 receptors/cell compared to 10,500 sites/cell for isolated cells. The 
affinity of B16 sections for 125I-NLDP was twice that of isolated cells with an average Kd 
values of 0.58 and 1.2xlO'9M, respectively.
1.7.5. CHARACTERISATION OF THE MELANOTROPIN RECEPTOR 
PATHWAY
Binding of melanotropins must occur on the extra-cellular surface in order for activation 
of MSH receptors. When a-M SH is applied to the outside of the cell, melanophores 
respond with melanin dispersion. Alpha-MSH injected intracellularly with micro- 
electrodes had no effect on melanogenesis (70,89).
Varga et al (183, 184) incubated Qoudman mouse melanoma cells for 15 minutes at 372C 
with p-MSH tracer and monitored the binding pattern of the peptide with auto­
radiography. He found the label clustered over the perinuclear area of the cell surface. 
Further studies with an a-MSH-ferritin-fluorescein conjugate displayed a patchy binding 
over the cell surface, and at areas adjacent to the nucleus (43). Legros et al (103) also 
observed the distribution of a-M SH on the human melanoma plasma membrane was 
patchy and limited to a defined area of the cell surface. Similar results were obtained with 
cultured guinea-pig melanocytes (57). The FTTC-(3-MSH probe accumulated specifically 
on the Qoudman melanoma cell surface, overlying the Golgi region. It was observed 30 
minutes later in Golgi vesicles (184,185). Varga suggested internalisation of the hormone
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is instrumental during induced melanogenesis because of the association of the a-M SH 
conjugate with Golgi regions and internal vesicles.
More recent experiments also support the hypothesis for receptor-mediated internalisation 
of the agonist-MSH-R complex by melanoma cells. Most of the evidence for MSH-R 
internalisation comes from acid treatment of melanoma cells during binding assays at 
metabolically active temperatures. Isotonic acid buffers are known to remove cell-surface- 
bound ligand, leaving only internalised a-M SH tracer behind (158). An a-MSH agonist 
was not observed within B16 cells following a 24 hour incubation at 42C (133). A 372C 
incubation on the other hand, demonstrated a time-dependent decrease in acid-soluble 
radioactivity with an initial increase, and eventual decrease, in acid resistant radio-activity. 
Internalisation was temperature dependent while the binding process was no t After a 4 
hour incubation at 37aC, degradation products of the tracer were found in the cellular 
sample, but not the medium. Panasci (133) claimed the interaction between melanotropins 
and their receptors was similar to other polypeptide hormones and their receptors; i.e. a 
process involving binding, internalisation, and hormonal degradation (lysosomal), with 
down regulation of the receptor in the presence of saturating hormone concentrations.
Eberle (52) confirmed these findings. After 10 minutes at 37SC, mouse melanoma 
internalised 28% of an iodinated photo-reactive melanotropin. After 7 hours, 75% of the 
ligand was internalised with 25% bound to the cell surface. At temperatures of 0-152C, 
internalisation of MSH peptides were considerably reduced or abolished. These results 
also imply down regulation of the MSH-R. Human DIO cells responded differently to a -  
MSH. After 30 minutes at 37fiC, only 4% of the ligand was internalised. After 3 hours 
internalisation did not exceed 10%. Desensitisation of the MSH-receptor system has been 
observed in S91 melanoma tumours. Adenylate cyclase activity, an enzyme involved in 
MSH-receptor signalling, is much lower after stimulation by a-M SH (101).
20
In other receptor systems occupied receptors of the cell plasma membrane will become 
associated with coated pits which invaginate into the cytosol to form coated vesicles 
containing the agonist-receptor complex (87). Consequently, internal binding sites for 
MSH are associated with coated vesicles (31, 33). Orlow et al. (132) claimed these 
internal binding sites for MSH are an important criteria for cellular responsiveness to the 
hormone. Coated vesicles from melanoma tumours also contained MSH regulated kinase 
activity (23, 31, 82). The internalisation of the hormone or the hormone-receptor complex 
may have played a role in the physiological response of the cells via the generation of 
second messengers (111).
1.7.6. CHARACTERISATION OF THE MELANOTROPIN RECEPTOR
The MSH receptor has been described as a single population on both mouse and human 
melanoma plasma membranes with Scatchard Plot analysis of saturation binding data. 
Proteins bound by the monoiodinated [Nle4J)-Phe7,Trp(Naps)9]-a-M SH conjugate 
identified similar receptors for both murine and human melanoma using SDS-PAGE 
techniques. A 45 kDa glycoprotein was selectively bound by a-MSH-photoaffinity labels 
in several B16 subclones, Cloudman mouse, and 3 human melanoma lines by 3 separate 
research groups (53, 152, 158, 166). The receptor was acidic with an isoelectric point of 
4.5-4.9.
Other experimenters observed a doublet band of 43 and 46 kDa for B16 melanoma (1, 
66). In human DIO cells a minor band was seen along side the 45 kDa protein (158). 
These results suggest two labelled proteins representing one class of receptor. 
Heterogeneity of melanotropin receptors of B16 subclones has also been demonstrated.
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Solca et al (167) identified 3 different forms of MSH-Rs on 3 B16 subclones with varying 
Kds (0.9-1.6x10® M) with different molecular weights (42,45 kDa, and a 43 and 46 kDa 
doublet).
The MSH-R has been further characterised by molecular cloning techniques. Qoudman 
mouse melanoma DNA clone (cDNA) libraries were constructed revealing a 317 amino 
acid protein with a molecular weight of 34.795 kDa (38, 126). It bound iodinated NLDP 
in a specific manner when expressed in COS-7 cells. Binding was displaced by the 
melanotropins a - , p-,y-M SH and ACIH.
A cDNA library has been encoded from a human melanoma with a large number of MSH 
binding sites. It produced a 2.1 kb clone which selectively bound melanotropins when 
transfected into other human cells. The amino acid sequence of this human MSH-R was 
76% and 39% identical and collinear with murine MSH-R and the human ACIH-R, 
respectively. This MSH-R protein might be universal for pigment cells. Several other 
human melanoma and two primary human melanocyte lines expressed small amounts of 
this MSH-R mRNA (126). An MSH-R gene 361 amino acids in length has been cloned 
from a human cervical cancer cell line (62). Its pharmacology characterised it as an a- 
MSH-R, specific to the heptapeptide core common to adrenocorticotropic hormone, a-, 
P-, andy-MSH.
The murine MSH-R contained seven hydrophobic segments of amino acids which were 
predicted to span the cell membrane 7 times. This transmembrane topography is 
characteristic of a G-protein-coupled receptor. One cytoplasmic loop and its COOH- 
terminal contained sequences for cAMP-dependent protein kinase recognition (38,126).
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1.8. MELANOTROPIN REGULATION OF INTRACELLULAR 
SIGNALLING OF MELANOMA CELLS
1.8.1. INTRODUCTION
Once occupied by an agonist, the MSH-receptor transduces the hormonal message across 
the cell membrane to an effector which generates one or several intracellular signals. 
Binding and activation of intracellular messengers by the occupied MSH-R is dependent 
upon available calcium. In pigment cells the major pathway(s) for the signalling of MSH 
across the cell membrane involves: 1) the stimulation of a Guanosine-triphosphate (GTP) 
regulatory protein; 2) which activates adenylate cyclase (AC); 3) followed by an increase 
of intracellular 3',5'-cyclic adenosine monophosphate (cAMP); 4) which induces the 
activation of protein kinase(s) and protein phosphorylation; 5) this is succeeded by RNA 
synthesis; 6) protein synthesis; and 7) tyrosinase activation (52)
1.8.2. MELANOTROPIN REGULATION OF PROTEIN(S)
The GTP-binding properties of the MSH-R have been described by the amino acid 
sequence of the purified receptor (38, 97). Non-hydrolysable GTP analogues or cholera 
toxin lead to long-lasting activation of melanophores and melanoma. Thus, the stimulation 
of adenylate cyclase (AC) by the activated hormone-receptor complex involved a GTP- 
stimulatory protein (15, 110). The affinity of MSH for its receptor was reduced by GTP 
(64). The regulation of the MSH-R affinity for ligands by GTP and calcium (Section
1.7.3.) might occur on opposite faces of the cell plasma membrane. The negative 
biofeedback system between the occupied receptor and the GTP protein suggests a means 
for receptor desensitisation.
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1.8.3. MELANOTROPIN REGULATION OF AC AND cAMP
MSH stimulated AC activity in both melanotic and amelanotic variants of Cloudman S91 
mouse melanoma (16, 17). It usually led to pigment dispersion via increased levels of 
cAMP and tyrosinase activity (84). Adenylate cyclase activity increased with decreasing 
carbohydrate content in the membrane. Membrane carbohydrates may participate in the 
hormonal responsiveness of the cell (153).
The MSH induced rise in cellular cAMP levels of murine melanoma reached 200-fold by 5 
minutes and returned almost to basal levels by 5 hours (48). Calcium was necessary for the 
transduction of the MSH-R signal. As with binding, AC was specifically inhibited by 
calmodulin inhibitors (65). Although the precise intracellular site of calcium is not known, 
it appears to lie functionally between the receptor, prior to AC stimulation (116).
1.8.4. MELANOTROPIN REGULATION OF PROTEIN KINASE(S) AND 
PROTEIN PHOSPHORYLATION
Protein kinases are known to modulate the activity of membrane transducing systems with 
specific phosphorylation reactions (178). Receptor phosphorylation is an important 
mechanism of controlling receptor desensitisation and internalisation. Activation of protein 
kinase A (PKA) and protein kinase C (PKC) were induced by MSH via the cAMP 
pathway in a dose-related manner (29). Two of three protein kinase isotypes found in 
melanocytes (a, p, and E) have been detected in melanoma ( a -  and P~; 203). In murine 
melanoma, the catalytic subunit of PKA was translocated to the nucleus after activation by
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cAMP (48). Protein kinase C potentiated the effect of a-M SH  but did not itself induce 
pigment dispersion (117). Protein kinase C is another suggested site of intracellular 
calcium regulation (119). The kinase is further controlled by diacylglycerols (131). 
Phorbol esters inhibited phosphorylation of the minor 34 kDa protein seen in S91 
Cloudman cells (52). These results suggest a relationship between PKA, PKC and 
receptor phosphorylation with the activated MSH-R. Transmembrane signalling of MSH 
appears to involve cAMP activation of protein kinases(s) and protein phosphorylation 
(52).
1.9. SCOPE OF THESIS RESEARCH
Alpha-MSH derivatives either alone, or conjugated to a toxin or probe, are potential 
agents for specifically targeting melanoma during diagnosis and therapy. The MSH 
agonist-receptor system needs to be more thoroughly described before it can be effectively 
manipulated against melanoma. A panel of MSH derivatives were synthesised and tested in 
binding and biological activity assays to help define the MSH-receptor pathway (1). It was 
necessary for these ligands to maintain a high degree of specificity for the MSH-R and 
respond biologically in order to describe the agonist-MSH-receptor complex and its 
metabolic fate. An a-MSH-toxin conjugate was developed and tested for site-selective 
delivery to the a-MSH-R of B16 melanoma cells.
There are several reports of activated MSH-receptor (MSH-R) complexes stimulating 
second messenger systems which result in reduced melanoma proliferation. Alpha-MSH 
may also inhibit growth causing the cytotoxic accumulaition of melanin by-products. 
Studies were performed on B16 mouse melanoma cells to clarify conflicting reports of 
stimulation, inhibition, or negligible effect of MSH on melanoma growth. The effects of
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a-M SH and a potent analogue were examined in chronic and pulse doses on cell 
monolayers in vitro.
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All water used for the preparation of cell culture media and solutions was freshly double 
glass distilled by a bi-distillation Fistreem still (Fisons Ltd) fitted with a Fistreem pre- 
dionizer (Fisons Ltd).
2.1.1.2. BALANCED SALT SOLUTION
Phosphate buffered saline without calcium and magnesium (PBS) was obtained from 
Oxoid Ltd in tablet form. Ten tablets were dissolved in 1 litre of freshly double distilled 
water and divided into 125 ml Flow bottles before steam sterilisation in an autoclave 
(British Steriliser Co. Ltd, Swingclave Type SFT-LAB) at 121CC for 15 minutes and 
stored at 4SC. No bottles were kept past 1 month.
2.1.1.3. BASE AND ACID SOLUTIONS
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Sodium bicarbonate (7.5%, NaHC03, BDH Chemicals), 1 N sodium hydroxide (NaOH, 
BDH Chemicals), and 1 N hydrochloric acid (HC1, BDH Chemicals) were prepared with 
double distilled water, steam sterilised and stored at room temperature.
2.1.1.4. ETHYLENEDIAMINETETRA ACETIC ACID
0.02% EDTA (BDH Laboratory Reagents) solution prepared in PBS was steam sterilised 
in 100 ml Row bottles. Twenty ml aliquots were put into sterile universals (Sterilin Ltd) 
and stored at -202C until required. No EDTA solutions were kept past 6 months.
2.1.1.5. TRYPAN BLUE
This stain was obtained from Sigma Ltd and stored at room temperature as a 0.1% 
solution in PBS.
2.1.1.6. GROWTH MEDIA AND ADDITIVES
RPMI 1640 (Row and Imperial Laboratories) was obtained as 10X sterile liquid 
concentrates containing phenol red and no L-glutamine or sodium bicarbonate. The 
following media supplements were all obtained sterile from Row or Imperial Laboratories 
and asepdcally divided into 20 ml aliquots, L-glutamine (200 mM), an antibiotic solution 
(pen/strep) of penicillin (5000 IU/ml) and streptomycin (5000 mg/ml) and non-essential 
amino acids (NEAA). RPMI 1640 media and NEAA were stored at 42C while L- 
glutamine and pen/strep were stored frozen at -202C.
Fetal calf serum (FCS) from Row and Gibco Laboratories was batch-tested for the 
support of cell growth supplemented at 10% to RPMI 1640 growth media. Maximum
2 8
growth occurred with batch numbers 9130012 (Flow) and 30A0212S (Gibco), used from 
26.3.90-16.8.91 and 16.8.91-1.10.92 respectively. Serum arrived in 500 ml bottles and 
were allowed to thaw completely before being mixed and stored at -20SC in 110 nil 
aliquots.
RPMI 1640 media was aseptically prepared from sterile components according to the 
following recipe, stored at 42C and used within two weeks. It was checked visually every 
day for contamination.







Occasionally media required a small addition (c. 1 ml) of sterile 1 N NaOH or HC1 to 
attain a final pH of 7.2-7.4.
2.1.2. PREPARATION OF REUSABLE ITEMS
All recycled items were rinsed in tap water immediately after use and then processed as 
follows. Glassware was soaked in a 2% solution of RBS 25 (Fisons Ltd) at approximately 
402C for 30 minutes, then thoroughly cleaned using a nylon brush. Articles were 
subsequently rinsed in three changes of tap water, and left for 30 minutes in the last rinse. 
The process was then repeated using single distilled water. Finally, all glassware was left
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to stand in a large volume of freshly collected double distilled water for no longer than 1 
hour. After drying in a hot air oven (Gallenkamp), all items were capped with aluminium 
foil and sterilised by dry heat at lbC^C (Gallenkamp Sterilising Oven) for a minimum of 1 
hour.
Non-glass items, mainly tips for replicating pipettes, bottle caps and syringes were rinsed 
immediately after use and then cleaned by boiling in three changes of fresh distilled water. 
Finally, they were rinsed and left for 1 hour in a large volume of freshly double distilled 
water, dried, sealed in autoclave bags (DRG Hospital Supplies) and sterilised in an 
autoclave (Drayton Castle Laboratory Steriliser) at 1212C for 15 minutes.
2.1.3. EQUIPMENT
Sterile tissue culture polystyrene flasks (25, 75, 150, and 175 cm2, Falcon, Becton 
Dickinson and Co.) and 24-well plates (16 mm diameter, Coming Cell) were regularly 
obtained from Imperial Laboratories. Clear, rigid polystyrene boxes (3.25 litres, 
Gallenkamp) sealed with gas tight vinyl tape (Intech Tapes Ltd) were used to house the 
24-well plates. Five, 10, and 20 ml screw capped universal containers were obtained from 
Sterilin Ltd. Polypropylene 2 ml ampoules with screw-caps were obtained sterile from J. 
Bibby Sciences and used for the storage of cells in liquid nitrogen.
All manipulations requiring a sterile environment were performed in a vertical recirculating 
laminar flow cabinet (MDH Ltd). Other experimental protocols were performed at the 
bench.
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All cells were stored in 2 ml ampoules, shelved in the vapour phase of a Union Carbide 
LR-40 liquid nitrogen refrigerator at approximately -148SC. Cells were maintained in a 
LEEC PF2 anhydric incubator (Laboratory and Engineering Company) with forced air 
circulation and thermostatic controls adjusted to give a temperature of 37CC. It was 
regularly checked with a digital thermometer with a thermocouple probe (Jenway Ltd) in a 
beaker of sterile water.
An inverted biological microscope WILD M40 (Wild Heerbrugg Ltd) was used for the 
examination of growing cell cultures and counting cells. A standard double grid 
haemocytometer (Fisons Ltd) was used to count cell density.
2.1.4. B16 CELL CULTURE METHODS
2.I.4.I. CELL LINE SUB-CULTURE
Sub-culture was undertaken weekly when the cells had reached confluence (roughly 2xl07 
cells/175 cm2) and the growth rate had almost ceased. In this state, the cells completely 
covered the floor of the tissue culture flask and further growth was limited by contact- 
inhibition and the availability of nutrients in the media. After this point, the media pH 
dropped below 7.0 and there was some cell detachment.
The culture was optically examined to ensure the cells were healthy with no free-floating 
cellular debris or contamination in the growth medium. Aseptically, the old media was 
decanted off and the monolayer was rinsed two times each with 5 ml of pre-warmed
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(37flC) sterile PBS. The flask was then incubated with 2 ml of pre-warmed 0.02% EDTA 
at 372C for 10-30 minutes.
Upon removal from incubation the flask was gently agitated to dislodge the cells from the 
substrate, and 5-10 ml of fresh media was added. Using a sterile plugged Pasteur pipette, 
the cell suspension was gently aspirated until well mixed, and 0.40 ml was put into a sterile 
test tube to determine cell density. A new 175 cm2 culture flask containing 100 ml of pre- 
warmed media was then inoculated with 106 cells and purged with 5% C 02 in air (BOC 
special Gases) for 30 seconds before the cap was tightly sealed. The flask was put in an 
incubator and checked every day for health and contamination until the following week.
2.1.4.2. DETERMINATION OF CELL DENSITY
Subcultured cells prepared in a suspension form were thoroughly mixed and 0.1 ml of 
trypan blue was mixed in with 0.4 ml of the suspension for 5 minutes while being gently 
agitated. Viable cells excluded the dye while non-viable cells were stained dark blue. A cell 
density count would only include the former.
A drop of the cell-dye mixture was loaded into a haemocytometer chamber under a 
coverslip pressed down such that interference patterns appeared along its edges. Each 
chamber was divided into 9 large squares by 3 white lines, the 4 comer squares were 
further subdivided in 16 squares/comer, and the central square was subdivided into 25 
smaller squares. A total count was made on the 4 comer and the central square of the 
haemocytometer grid with an inverted microscope.
If cell clumping was observed the count was abandoned and the cell suspension was 
further aspirated and a new sample was taken. If the cell density was greater than 150
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cells/chamber then counting was impeded by overcrowding and the cell suspension was 
diluted before a new count was attempted. Conversely, if the cell count was below 25 
cells/chamber the cell suspension was concentrated by centrifugation (1000 rpm for 5 
minutes). A new cell-dye suspension was prepared if manipulations took longer than 15 
minutes due to cell death from exposure to the dye.
Since each large square had an area of 1 mm2 and a depth of 0.1 mm with the coverslip 
on, the total volume for each square was 10"4 m l Where N is the mean of the 5 large 
squares, the cell density of the cell suspension was NxlO4. To account for the dilution of 
the cell suspension with the dye, the end equation was 5(Nxl04/4). Cells counted in this 
manner gave a standard deviation of 7.4% for 4 separate readings of a cell suspension.
2.I.4.3. CELL STORAGE
All cells were routinely stored frozen in liquid nitrogen, or its overlying vapour, after 
exposure to 10% of the cryoprotectant dimethyl sulphoxide (DMSO, BDH Chemicals 
grade 1, stored at room temperature in a dark glass container). Cell suspensions were 
prepared from the monolayer state during routine sub-culture, and centrifuged at 1000 
rpm for 10 minutes (Jouan B3-11 bench centrifuge). The supernatant was removed and 
the cell pellet resuspended in a volume of filter-sterilised (0.2 jim sterile filters, Gelman 
Sciences) growth media containing 10% DMSO for a cell density of 2x10® cells/ml. 
Replicate volumes of 1 ml were placed in 2 ml polypropylene ampoules with a maximum 
of eight placed in a Union Carbide BF6 biological freezer unit plug, in the top of a Union 
Carbide LR 33-10 liquid nitrogen refrigerator. Here the cells were cooled to below -7 0 ^  
in nitrogen vapour at a rate of approximately l aC/minute before being transferred to a 
liquid nitrogen freezer for long term storage.
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2.1.4.4. RECOVERY OF CELLS FROM STORAGE
Immediately upon removing ampoules from storage they were placed in a 372C water 
bath, ensuring that the water did not ride above the screwcap. They were swabbed with 
70% ethanol (Haymans Methylated Spirits diluted with H20) when completely thawed and 
the contents were aseptically transferred into a 175 cm2 flask containing 100 ml 
prewarmed media. After 4-5 days the cells formed a monolayer suitable for routine 
subculture.
2.1.4.5. PREPARATION OF CELLS IN 24-WELL PLATES
The cell density was determined for a cell suspension from a confluent monolayer during 
routine subculture before inoculation into 24-well plates. For all binding isotherms and 
assays, wells were seeded with 5x10s cells/welL Unless stated otherwise, wells for the 
tyrosinase assays were seeded with 3X104 cells/well. Wells for cell growth experiments 
were inoculated with 2.4xl04-5xl05 cells. All wells were filled (total volume 3 ml) with 
media and placed in a clear polystyrene box containing a 100 ml beaker of distilled water 
to maintain humidity. The box was then purged with 5% C 02 for 3 minutes and sealed 
with gas tape. Following an overnight incubation at 3 7 ^ , the cells were ready for 
experimental use.
2.2. SYNTHESIS OF PEPTIDES
Samples of [Nle4-DPhe7]-a-M SH (NLDP) and a-M SH were obtained from Sigma 
Chemical Co. for reference with peptides synthesised in our laboratory. All other peptides
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and further batches of NLDP and a-M SH were prepared by Dr. G. W. Olivier, therefore 
the protocol for their manufacture will not be described in full (Appendix 1). Prior to 
experimental use the peptides were dissolved 1 mg/ml in sterile 0.1 mM HQ and stored 
sterile at 4SC in a plastic screwtop-top eppendorf (Sarstead Plastics). All manipulations of 
peptides took place with plastic equipment due to the 'sticky' nature of a-M SH analogues.
2.3. IODINATION OF PEPTIDES
All tracers followed the same format for iodination using the equimolar chloramine T 
procedure (52). The photoaffinity tracers were not exposed to light during their 
manipulation and stored in foil-wrapped eppendorfs. They could not be monitored with 




The following stock solutions were routinely prepared and stored at 4®C:
1) 0.25 M Na2HP04 (FSA Laboratory Supplies) in H20 .
2) 0.25 M NaH2P04 (FSA Laboratory Supplies) in H20 .
3) 1% TFA (trifluoroacetic acid, Aldrich Chemical Co., HPLC grade) in H20 .
4) 50,60, and 80% methanol (FSH Chemical Co., HPLC grade) with 1% TFA.
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5) 0.1% TFA in H20  (HPLC solvent A).
6) 70% acetonitrile/0.1% TFA (HPLC solvent B)
2.3.1.2. FRESHLY PREPARED SOLUTIONS
The following solutions were prepared fresh the day of each iodination:
1) 0.25 M phosphate buffer (PB), pH 7.4 (from Na2HP04 and NaH2P 04 stock
solutions).
2) 0.25% BS A (bovine serum albumin, Sigma Chemical Co.) in 0.05 M PB.
3) 1% Polypep (Sigma Chemical Co.) in 0.05 M PB.
4) 0.1% chloramine T (BDH Chemicals Ltd) dissolved immediately prior to use in
h 2o .
23.2. PREPARATION OF THE COLUMN
Iodinated peptide was initially purified with a C l8 reverse-phase column with Spherisorb 
ODS 'Bond Elut1 (Analytical International, MFG code OH53). The column was prepared 
and conditioned with the following 1 ml wash routine:
1) 3x1% TFA.
2) 3x80% methanol/1% TFA.
3) 1x1% Polypep in 0.05 M PB.
4) 3x80% methanol/1 % TFA.
5) 3x1% TFA.
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2.3.3. IODINATION OF PEPTIDES
A 1.5 ml plastic eppendorf containing 0.02 ml of 0.25 M PB and 1.5 |il of peptide (from 
the 1 mg/ml stock) was transferred to a radioactive fume hood for the addition of 1.5 mQ 
Na-125I (ICN Biomedicals, Inc). This was followed by 0.01 ml of freshly prepared 0.1% 
chloramine T which started the reaction. After 30 minutes 0.6 ml of 0.25% BSA in 0.25 M 
PB was added to halt the reaction and bind unbound 125I2.
2.3.4. PURIFICATION OF THE TRACER
The eppendorf contents were loaded onto the pre-conditioned Cl 8 column. The column 
received the following 1 ml washes:
1) 2x0.25 MPB.
2) 4x50% methanol/1 % TFA.
3) 2x60% methanol/1 % TFA.
The last two sets of washes were saved (6 ml in total) and the peptide was further purified 
by HPLC using a C l 8 reverse-phase wide pore (300 A0) column, 25 cm in length and 4.6 
mm in diameter. The methanolic washes were loaded onto the column which was run with 
an exponential gradient starting at 95% A, 5% B, reaching 40% A, and 60% B after 55 
minutes before returning to the original values. A UV detector was employed at 217 nm (a 
HPLC trace of 125I-NLDP is listed in Appendix 1). Ten 1 ml fractions were collected after 
28 minutes (flow rate 1 ml/minute) and their activity was assayed on a gamma-counter.
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The monoiodinated compound usually came off the column between 30-36 minutes, 
separating the free NLDP (usually 3 minutes earlier) and the diiodinated compound 
(usually 3 minutes later). The tracers were stored up to two weeks at -202C in HPLC 
buffer without signs of degradation.
23.5. PREPARATION OF STREPTAVIDIN TRACERS
Monoiodinated biotinylated-streptavidin-NLDP ((Sa)-Bi-125I-NLDP) was freshly prepared 
by adding iodinated Bi-NLDP : streptavidin (Sigma Chemical Co.) diluted in sterile PBS 
for a 4:1-1:25 molar ratio. The mixture was gently shaken for 30 minutes at room 
temperature and added to an excess of Dynabeads M-280 streptavidin (100 ml : 100 
mg/ml, Dynal, Merseyside) prewashed in PBS with 0.02% sodium azide (Sigma Chemical 
Co.) and stored at 42C. The solution was gently shaken at room temperature for 30 
minutes to remove free Bi-125I-NLDP (1). The supernatant containing streptavidin bound 
Bi-125I-NLDP was assayed on the gamma-counter. The Dynabeads activity was assayed to 
measure the amount of free Bi-125I-NLDP. If there was a substantial amount of unreacted 
Bi-125I-NLDP (above 4X106 cpm), the amount of streptavidin was increased until very 
little unbound 125I-NLDP was associated with the beads (99%). This was to assure that 
free Bi-125I-NLDP did not contaminate the solution of (Sa)-Bi-125I-NLDP. The mixture 
ratio of Bi-125I-NLDP to streptavidin was kept between 4:1-1:25 to allow theoretical 
optimal binding of the biotin molecule for streptavidin (4:1), while keeping non-specific 
binding of free streptavidin to a minimum. Monoiodinated biotinylated-streptavidin-gold- 
NLDP ((Sa-Au)-Bi-125I-NLDP) was prepared following the same protocol using 10 nm 
streptavidin-gold conjugates (Sigma Chemical Co.).
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2.4. RADIO-IMMUNOASSAY FOR a-MSH IN FETAL CALF 
SERUM
All materials and methods followed the experimental format of Bowley et al (26).
2.4.1. SOLUTIONS
2.4.1.1. ASSAY BUFFER
The assay medium was a gelatine/phosphate buffer containing 0.05 M sodium-phosphate, 
pH 7.5,0.1% gelatine (Davis), and 0.9% sodium-chloride (NaQ, BDH Chemicals).
2.4.1.2.<x-MSH ANTIBODIES
Alpha-MSH antibody plasma (R6FB, 26) was stored at 42C, and diluted 1:100 in assay 
buffer. This stock solution was stored for months without a loss in activity. The stock was 
diluted 1:150 in buffer (33 ml/5 ml) before use.
2.4.1.3. a-MSH STANDARDS
Alpha-MSH standards are prepared by dissolving 1 mg a-M SH (Sigma) in 1 ml of 0.01 
M HCL and 0.25% BSA. This solution was then diluted in medium containing 0.25%
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BSA for a final a-M SH concentration of 4 ng/ml. Half ml aliquots were then put into 4 ml 
polyethylene assay tubes (Bibby) and stored at ^(FC.
2.4.1.4. CHARCOAL SOLUTION
A Charcoal/dextran solution was prepared by combining 1% Norit A charcoal (FSA 
Laboratory Reagents, dried for several days at KXFC) with 0.1% dextran T 70 (Sigma 
Chemical Co.) made up in assay medium (26). The solution was kept homogeneous by 
continuous stirring during the assay. All solutions and samples were kept on ice during 
preparation of the radio-immunoassay.
2.4.2. RADIO-IMMUNOASSAY PROCEDURE
2.4.2.1. DAY ONE
The a-M SH standard curve was prepared by the addition of 0.2 ml buffer, 0.1 ml 
standard a-M SH, and 0.05 ml a-M SH of the antibody solution in polyethylene LP4 tubes 
(Luckham Ltd LP4 gamma-counter tubes). The serum standard curve was prepared by 
replacing 0.1 ml of the assay buffer with 0.1 ml of FCS passed through a set-pack 
(conditioned as for iodination, Section 2.3.2.). Samples were tested for a-M SH  by 
replacing the standard with 0.1 ml samples of FCS. Each tube was vortexed before the 
addition of 0.05 ml of 125I-a-M SH (prepared by the chloramine T method, Section 2.3.) 
containing 2500 cpm in buffer. The solution was again vortexed and incubated at 4®C for 
2 days. Ten doubling serial dilutions of the hormone standard were used for the standard
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curves. All hormonal concentrations and samples were prepared in duplicate. Zero 
concentrations and reagent blank tubes were included in each assay.
2.4.2.2. DAY THREE
After 2 days, the separation of free from bound 125I-a-MSH tracer was achieved by 
adding 0.5 ml of ice-cold charcoal/dextran solution to the tubes. They were vortexed and 
incubated at 42C for 10 minutes. The tubes were then centrifuged (2000 ipm) at 42C for 
15 minutes and the supernatant was quantitatively aspirated. The pellets were counted on 
a gamma-counter for 5 minutes. Each assay was repeated twice.
2.4.2.3. CALCULATIONS
Counts due to non-specific binding were deducted from all values and the standard curve 
was plotted as %B/Bo, where:
B = tracer bound in the presence of unlabelled peptide.
Bo = tracer bound in the absence of unlabelled peptide, 
non-specific = tracer bound with excess unlabelled peptide.
2.5. BINDING OF a-MSH ANALOGUES TO B16 CELLS
2.5.1. BINDING BUFFER
The buffer for binding assays was prepared fresh the day of the assay and maintained at 
the incubation temperature used during the assay. It consisted of a RPMI 1640 sterile
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solution without additives, containing 25 mM 4-(2-hydroxyethyl)-l- 
piperazineethanesulphonic acid (HEPES, BDH Biochemicals), 0.2% BSA, and lOMO*10 
M 125I-NLDP. In some cases, a synthetic collagenase inhibitor and 1,10-phenanthroline 
were added to the binding buffer for final concentrations of 10-10-10-7 M and 0.3 mM 
respectively.
The following stock solutions were:
1) 0.25 M HEPES buffer pH 7.2-7.4.
2) 2% BSA.
3) 10'2 M synthetic collagenase inhibitor (molecular weight 379, SmithKline and
Beecham).
4) 1 M 1,10-phenanthroline (Sigma Chemical Co.).
The HEPES and BSA stock solutions were made-up in RPM I1640 media and stored in 5 
ml aliquots at -202C. The stock buffers were good for 6 months. The synthetic collagenase 
inhibitor and 1,10-phenanthroline were stored in ethanolic solutions, also at -20^.
2.5.2. BINDING ASSAYS OF ^I-N LD P AT 0-4*C
Media from wells seeded overnight with 5x10s celWwell was removed and the number of 
cells in 4 sample wells were counted. This cell density produced a confluent monolayer of 
cell on the well floor. Cells were not used unless they were confluent Other wells were 
washed twice with 3 ml of sterile RPMI 1640 media without FCS, NEAA, Pen/Strep, or 
glutamine, which had been cooled to 42C. The last wash was left in the wells and the 24- 
well plates were put on ice at 4®C for 30 minutes. In this way the cells were brought down 
to 1.5-42C (as measured by a thermocouple probe). The second wash was removed from
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the wells and replaced with 0.5 ml of ice-cold binding buffer. The 24-well plates were put 
on ice in a a plastic box sealed with gas tape, with an atmosphere of 5% C02, and 
incubated at 4SC for 1 minute to 24 hours. After the incubation, the cells were washed 
twice with 3 ml of ice-cold serum free media and detached from the wells in 0.5 ml 1 M 
NaOH, and put into LP4 tubes where their activity was counted on a LKB Wallac 1277 
Gammamaster. Non-specific binding was assessed by adding an excess (10* M) unlabelled 
NLDP to the binding buffer.
Extemal-cell-surface binding to a-M SH receptors was evaluated by determining the 
dissociation of bound tracer after a 5 minute acid wash in 0.5 ml of ice-cold PBS pH. 2.0. 
The pH of the PBS was compared with an add solution of a known pH of 2.0 
(Documenta Geigy). The solution consisted of 2 ml 0.2 N KQ (potassium-chloride, FSH 
laboratory supplies) and 5.9 ml 0.2 N HCL Cellular internalisation of the tracer was 
estimated by subtracting non-specific binding from wells treated with the add wash.
2J53 . BINDING ASSAYS OF U5I-NLDP AT 15 AND 37aC
Binding assays were also performed at 15 and 372C. They followed the same procedure as 
the 4SC isotherm except for the pre-incubation and incubation temperatures. The cells 
were washed, pre-incubated, and incubated in buffers at 15 or 37SC, respectively. The 
cells were incubated in a Grant Instruments water bath at 15fiC or in an incubator at 37fiC.
2.5.4. COMPETITION BINDING ASSAYS
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The dissociation (Kd) and association constants (Ka) for a-MSH derivatives were 
determined using competition binding assays. The protocol was similar to the 4SC binding 
assays with an incubation time of eight hours. A concentration series of a competitive 
unlabelled analogue was added to the binding buffer. The tracer concentration in the 
binding buffer was roughly 10*10 M. In all cases, the radio-tracer used was 125I -NLDP 
with a known dissociation constant (Kd, determined with 4SC saturation binding isotherms 
and Scatchard Plot analysis, Section 2.5.6.1.). The Kd of NLDP was estimated by 
competition with 125I-NLDP (Section 2.5.6.2.). The binding affinity of the other radio- 
iodinated analogues was determined by competing these tracers with serial dilutions of 
unlabelled NLDP. Maximum binding and complete inhibition of the tracers was established 
with, respectively none, or an excess of (106 M), cold competitor to the binding buffer.
2.5.5. CALCULATION OF TRACER CONCENTRATIONS
The maximum specific activity of 125INa is 80.5x1012 Bq/matom. Assuming maximum 
specific activity of 125INa and a 1:1 ratio of 125I : NLDP; and since:
1 matom 125I = 103 moles 125I-NLDP 
1 mole 125I-NLDP ■ 80.5xl012xl03 Bq.
Since 1 Bq equals 1 decay/sec:
1 mole 125I-NLDP a 80.5xl012xl03x60 dpm.
Since our gamma-counter has 70% counting efficiency:




The number of counts per minute equivalent to 0.5 ml 1M 125I-NLDP is given b y :
= 1.69xl015 cpm.
The same calculations were performed for tracers of other a-MSH analogues.
2.5.6. RADIO-LIGAND-a-MSH RECEPTOR BINDING ANALYSIS
2.5.6.1. SCATCHARD PLOT ANALYSIS OF SATURATION BINDING ISOTHERMS 
AT0-4eC
Ligand-receptor interactions were analysed with MINSQ non-linear regression analysis 
with a weight of 1, and Equation 2.5.6.1. using data transformed from Scatchaid Plots 
(22y 112). According to the Law of Mass Action :
[H] = the concentration of free hormone.
[R] = the concentration of free receptor.
[HR] = the concentration of the hormone-receptor complex.
Ka = the rate constant of [HR] association 
= [HR]/[H][R].
Kd = 1/Ka
= rate constant of [H][R] disassociation.
Ka
at equilibrium [H][R]^------>  [HR].
Kd
n = total number of receptors
= [HR] + [R].




Equation 2.5.6.I.: Ka(n)-Ka[HR] = [HR]/[H].
These calculations give an equation for a straight line where: 
y axis = [HR]/[H]. 
x axis = [HR], 
slope = -Ka.
x-intercept (where y = 0) = n. 
a straight line = one population of receptors, 
a curvilinear line = a mixture of receptors.
During binding assays:
% receptor-specific bound = (total bound - nonspecifc bound)xl00%.
total bound
2.5.6.2. ASSUMPTIONS OF SCATCHARD PLOT ANALYSIS
During a Scatchard Plot analysis certain assumptions are made (22):
1) the labelled hormone is biologically identical to the native hormone.
2) the labelled hormone is homogeneous.
3) the receptor is homogeneous.
4) the receptor acts independendy.
5) the receptor is unoccupied.
6) the reaction is at equilibrium.
7) there is no non-receptor binding.
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2.5.6.3.ANALYSIS OF COMPETTnON ASSAYS
During competition binding assays the following Equation 2.5.6.2. was used to calculate 
dissociation constants for unlabelled a-MSH analogues competed against a tracer:
cpm test = ((cpm max -cpm min) [A]) + cpm min.
[A] + (KdA)([B]/KdB)
Where:
cpm test = cpm bound for sample point
cpm max = maximum bound cpm.
cpm min = minimum bound cpm (non-specific),
receptor specific cpm = cpm max - cpm min.
A = tracer.
B = unlabelled competitor.
the relative % maximum binding of the tracer [A] i s :
% max binding= cpm test - cpm min 
cpm max- cpm min
the curve is fitted a s :
% max binding = [A]
[A] + (KdA) [B]/KdB.
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For most competition assays, unlabelled a-MSH analogues were competed against the 
125I-NLDP tracer with a known Kd (determined by 0-42C saturation binding isotherms and 
Scatchard Plot analysis). The Kd of unlabelled NLDP was determined by competition with 
125I-NLDP. The Kds of other tracers of a-MSH analogues were then calculated by 
competition with unlabelled NLDP. To avoid a loss of more than 10% of the [HR] due to 
dissociation of [H] and [R], the allowable separation times of free [H] from bound [H] 
was 10 seconds-2.9 hours for a [H] with a Kd of 10*9-10'11 M, respectively (112).
2.6. TYROSINASE ACTIVITY ASSAYS
2.6.1. SOLUTIONS
2.6.1.1. ASSAY MEDIUM
The medium used during the tyrosinase assay was RPMI 1640 media containing additives 
and [3\5'-3H]-L-tyrosine (>50 Ci/mM, Amersham Co.) at 0.2 pCi/ml. The media also 
contained fresh serial dilutions of a-M SH peptides. Alpha-MSH or its analogues were 
not added to control wells. The [3\5f-3H]-L-tyrosine stock 1 Cui/ml was stored at 4®C for 
6 months. The media was aseptically prepared in plastic vessels the day of the assay.
2.6.1.2. CHARCOAL SOLUTION
A solution containing 10% dried charcoal in sterile PBS was used to separate [3 '^’-3H]-L- 
tyrosine from 3H20  (144). The solution was prepared fresh and kept in an ice cold 
homogeneous state.
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2.6.2.3H20  STANDARD CURVE
To measure 3H20  production during tyrosinase assays a quench curve was established on 
the LKB Wallac 1215 Rackbeta liquid scintillation counter using 3H -0 internal standards 
from Pharmacia (Internal standard kit for liquid scintillation counting 3H20  for organic 
solvents 3H -0 ,0.0909 mCi or 3.36 kBq activity/capsule, Appendix 1).
The protocol for the standard curve was as follows:
1) 8 ml organic scintillation fluid (OpitiPhase 'Safe', LKB Scintillation Products)
was added to 10 x 10 ml Beta-counter vials (polyethylene, Packard 
Chemicals and Supplies) with an internal standard capsule/vial.
2) 1 ml of distilled water was added to each vial after the standard had dissolved in
the scintillation fluid.
3) 0,10,20,30,40,50,60,70,80, or 100 ml of the quenching agent
carbontetrachloride (C d 4, Sigma Chemical Co.) was added to the vials.
4) the vials were vortexed and allowed to equilibrated for one hour at 42C before
the curve was programmed into the Beta-counter.
2.6.3. TYROSINASE ASSAY PROCEDURE
B16 mouse melanoma cells were seeded in 24-well plates overnight (Section 2.1.4.5.). 
One ml of fresh assay media was added to the wells replacing the overnight growth media.
The cells were placed in pre-gassed air-tight boxes and incubated at 372C for 1-3 days. 
After incubation, 0.90 ml of the supernatant was removed and put into 1.5 ml plastic 
eppendorfs (with air-tight lids) containing 0.4 ml of charcoal solution. The eppendoifs and 
plates were placed on ice to minimise 3H20  evaporation during manipulations. The 
eppendorfs were then vortexed and shaken for 15 minutes per hour at 42C. They were 
revortexed and centrifuged at 800 ipm for 15 minutes. The clear supernatant (0.9 
ml/eppendorf) was transferred into Beta-counter vials containing 8 ml of scintillation fluid. 
They were vortexed again and equilibrated for 1 hour at 42C, in the dark, before they were 
read by a Rack Beta Counter.
2.6.4. CALCULATIONS FOR Ec50 VALUES
The half-maximal biological activation of tyrosinase was measured by the water by­
product. Values were calculated with dose/response curves using INSTAT linear 
regression analysis. The equation for a straight line is y = mx + c where: 
y = response in dpm. 
x = concentration dose.
M = the slope of the line.
Where:
C = y axis-intercept 
x = log concentration agonist 
= log[A] 
dpm = M log [A] + C. 
log [A] = (dpm - C)
M
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The values for M and C were obtained from the linear portion of a dose/response curve. 
These values enabled the Ec50s (half-maximal biological stimulation) to be calculated. The 
Ec50 takes place where:
50% maximum increase in activity = dpm min + 1/2 x dpm specific.
Equation 2.6.4.:
Ec50 = antilog (dpm min + (1/2 x dpm specific - C)/M). 
dpm min is the activity obtained in the absence of agonist 
dpm max is the maximum activity associated with the agonist 
dpm specific is dpm max - dpm min.
2.7. GROWTH INHIBITION OF B16 CELLS BY a-M SH AND 
NLDP
2.7.1. CHRONIC DOSING WITH a-MSH AND NLDP
B16 mouse melanoma cells were seeded (2.5xl04-5xl05) into 24-well plates overnight 
The seeding media was replaced with 3 ml of pre-warmed RPMI growth media containing 
10n-10-7 M NLDP or 10-9 M a-MSH. Control wells contained hormone-free media. The 
cells were incubated at 37CC for 24 hours, the hormone-media was removed and the cells 
were washed twice in 3 ml of sterile PBS before the process would be repeated daily for 
1-6 days. After incubation, the cells were counted on a haemocytometer and their 
morphology, melanin production, cell growth characteristics, and media condition were 
assessed.
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2.7.2. PULSE DOSING WITH NLDP
Cells (seeded 5X104 c/well) were exposed to a daily 10-9 M pulse of NLDP over 4 days. 
The cells were exposed to the hormone-media for 30 minutes at 372C before the media 
was removed and the cells were washed twice in 3 ml of PBS. Three ml of hormone-free 
media was added to each well and the plates were incubated at 37SC until treatment the 
next day.
Growth inhibition of B16 cells was calculated with Equation 2.7.:
% growth inhibition = [l-(mean no. of treated cells/mean no. of untreated cells)]xl00%.
52
3. RESULTS
3.1. DETERMINATION OF ENDOGENOUS a-MSH IN CULTURE 
MEDIA
It was necessary to determine the amount of endogenous alpha-melanocyte-stimulating 
hormone (a-MSH) in the cell culture media to accurately assess the response of the 
B16 mouse melanoma cells to hormonal binding and stimulation (Section 2.4., 26). 
Figure 3.1. shows the standard curves of an a-M SH radio-immunoassay. One curve 
contained hormone free fetal calf serum. Samples of fetal calf serum used in cell 
culture work were compared to the serum standard curve to evaluate the presence of 
a-MSH. Alpha-MSH was not detected in any sample (data not shown). These results 
were confirmed in replicate assays. It is deduced that all hormonal effects observed 
with a-MSH and its analogues were due solely to experimentally added ligand.
3.2. BINDING OF a-MSH ANALOGUES TO B16 CELLS
3.2.1. INTRODUCTION
Studies of the binding of ligands to the a-MSH-R and the fate of the ligand-a-MSH 
receptor complex, are a primary concern in understanding the hormonal influence of 
a-M SH on the cell. This work can be advanced with melanotropin probes specific for
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the a-MSH-R. Specific binding of a-MSH analogues also provide the basis for future 
cancer therapy studies using a-MSH-toxin conjugates to specifically deliver drugs to 
melanoma. Internalisation of the a-MSH-receptor complex may be necessary to 
achieve melanoma cytotoxicity with chemotheraputic agents selectively delivered via 
the a-M SH receptor (a-MSH-R). Scatchard plot analysis of saturation binding 
isotherms with the 125I-NLDP tracer provide an estimation of : 1) the number of 
receptors/cell; 2) the level of receptor heterogeneity within the cell plasma membrane; 
and 3) the affinity of the a-MSH analogue for its receptor.
Competition of an agonist with another with a known affinity constant (Kd), allows the 
Kd of the former ligand to be determined. This information allows for the 
characterisation of the hormonal binding sequence of a-M SH and its receptor. It 
enables researchers to design new a-M SH analogues with strong affinities for the a -  
MSH-R. These compounds might serve as tools in further receptor research, or as 
targeting agents to cells expressing the a-M SH receptor.
3.2.2. BINDING OF ^I-N LD P TO B16 CELLS AT 37fiC
A modification of Eberle’s binding assay (52) was developed with the a-MSH 
analogue [Nle4,D-Phe7]-a-MSH (NLDP) to establish specific binding of a-M SH to 
receptors of B 16 cells. Details of the procedure are described in Section 2.5.
3.2.2.1. EFFECTS OF MULTIPLE WASHES ON BINDING
After incubation in a binding buffer containing approximately 1.18x1010 M 125I-NLDP, 
the cells were rinsed 1-4 times in 3 mis of RPMI 1640 medium. There was a rapid
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initial rise in binding, reaching a plateau after 2 hours (Figure 3.2.1.). One to two 
washes gave the highest level of binding with the lowest amount of intrasample 
variability as displayed by their smaller standard deviations. The data from 3 and 4 
washes was twice as scattered from their means than data obtained from 1 and 2 rinses. 
Washing the cells more than 2 times often dislodged cells from the monolayer. This is 
the likely cause for the greater variability observed with more than two washes.
3.2.2.2. EFFECTS OF INCUBATION MEDIUM AND BSA ON BINDING 
ASSAYS
The suitability of RPMI 1640 (Flow Inc.), Modified Eagles Medium with Earles Salts 
(MEM, Gibco) and phosphate buffered saline (PBS) binding buffers were tested in 
binding experiments. The 125I-NLDP binding assay employed by Siegrist et al. (157) 
contained 0.2% BSA to reduce non-specific binding. It was possible that this large 
protein might inhibit specific binding in these assays. Hence, RPMI 1640, MEM and 
PBS binding buffers in the presence and absence of 0.2% BSA were examined for 
specific and non-specific binding of the tracer to the cells (Figure 3.2.3.), and the 
polystyrene well plates (Figure 3.2.2.).
Cells incubated in the RPMI and MEM buffers (Figures 3.2.2. and 3.2.3.) showed 
binding profiles similar to the one observed in Figure 3.2.1.. Maximum specific binding 
was reached at 1 hour, followed by the loss of tracer from the cells until a plateau was 
reached after 2 hours. Binding of 125I-NLDP in the PBS binding buffer on the other 
hand, did not have this binding pattern. The PBS buffer displayed a reduction in bound 
ligand after 0.5 hours with a plateau after 1-2 hours (Figure 3.2.2.). Specific cellular 
binding was lower in MEM or PBS media than in the RPMI buffer (Figures 3.2.2. and
3.2.3.).
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Non-specific binding of the tracer to wells of the assay plates in either RPMI or PBS 
buffers, in the absence of cells, with or without 0.2% BSA, were comparable at 1 and 
2 hours (Figure 3.2.2.). Non-specific binding to the cells was determined with the 
addition of 10-6 M cold NLDP to the binding buffer (Section 2.5.). Percent non­
specific binding was calculated as the non-specific bound /  total bound, times 100%. It 
was higher in the MEM buffer (33%) than the RPMI recipe (23.5%, Figure 3.2.3.). 
This resulted in greater specific binding of the tracer in the RPMI binding buffer.
The RPMI buffer containing 0.2% BSA maintained the highest level of cell-associated 
binding for the longest period, with the lowest background binding to the wells (Figure
3.2.2.). BSA did not interfere with the binding of 125I-NLDP to the cells. Neither the 
maximum cellular cpm, specific binding, or the rate of the ligand-receptor reaction 
time, were altered with the addition of 0.2% BSA. BSA continued to be used in the 
binding buffer to safeguard against non-specific binding during longer assay 
incubations. The RPMI based binding buffer containing 0.2% BSA was used in future 
experiments.
3.2.2.3. EFFECTS OF 1,10-PHENANTHROLINE ON BINDING ASSAYS
Protein endopeptidases are secreted by melanoma cells (42). These might prolong the 
time necessary for a ligand to reach equilibrium by continually degrading the tracer 
during binding incubations. Siegrist et al. (157) found 1,10-phenanthroline stabilised 
[Nle4]-a-MSH over 2 hours at 372C in the presence of mouse B16 or human D10 
melanoma. He observed 1 and 0.3 mM 1,10-phenanthroline were the best 
concentrations for inhibiting tracer degradation and non-specific binding (less than 
25%) for D10 and B16 cells, respectively. Non-specific binding was measured in the 
presence of excess unlabelled ligand. Contradictory information (14) suggested such 
high levels of this metallo-protease inhibitor would be cytotoxic to the cell and reduce
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ligand-receptor activity. Thus, binding assays were performed with and without, 0.3 
mM 1,10-phenanthroline on B16 melanoma at
Experiments performed in binding buffers containing 1.03xl0-10 M 125I-NLDP 
displayed maximum binding at 1 hour which dropped to a plateau after 2 hours (Figure
3.2.4.). The binding profile of the buffer containing 1,10-phenanthroline was similar to 
the one without (Figure 3.2.4.). Although, the amount of specifically bound tracer was 
reduced (35.5%) with the addition of 1,10-phenanthroline. These results were 
confirmed in repeated assays. The protease inhibitor was not included in future binding 
buffers.
3.2.2.4. POSSIBLE INTERNALISATION OF 125I-NLDP
Internalisation of specifically-bound tracer at 37SC is partially established with acid 
stripping. Panasci ex al. (133) used 0.2 M acetic acid pH 2.5 to remove surface-bound 
(3H)ND4_n a-M SH from B16 FI cells. This technique exposed B16 cells to a low pH 
which effectively degraded the ligand and altered the receptor binding conformation. 
Thus, removing specifically receptor-bound ligand from the cell external plasma 
membrane. The freed ligand was washed away leaving any internalised ligand intact. 
Details of this procedure are described in Section 2.5.2..
Figure 3.2.5. shows the total amount of acid resistant tracer bound by B16 mouse 
melanoma cells at 372C over 4 hours in 1.18x1 O'10 M 125I-NLDP. Only 4.7% of the 
tracer was acid resistant after 1 minute, 15.8% after 0.5 hours, with maximum acid 
resistance plateauing after one hour (26.0-33.2%). Non-specific binding was minimal 
(3.3%). This pattern of results was observed in replicate assays.
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3.23 . BINDING OF 125I-NLDP TO B16 CELLS AT 152C
Binding assays were performed at 152C over 25 hours, with 1.08xl0-10 M 125I-NLDP. 
These assays followed the same experimental format as described earlier, except the 
B16 when cells were incubated at 152C instead of 372C. Figure 3.2.6. shows the 
relatively rapid occupation of extracellular sites over 6 hours. After this time, there was 
a slow accumulation in the number of external binding sites. This increase did not 
appear to reach a plateau after 6 hours. It is difficult to assess the equilibrium time 
necessary for the ligand-binding equilibrium, due to lack of data points between 6 and 
25 hours. There was no reduction of the externally bound ligand with time as 
witnessed at 372C. Conversely, intracellular radioactivity steadily rose over the 
incubation period, reaching a maximum of 42.1% after 25 hours. Non-specific binding 
was consistently 2-4% after 1 hour.
3.2.4. BINDING OF 12SI-NLDP TO B16 CELLS AT 0-4°C
3.2.4.1. EFFECTS OF ACID WASHES ON BINDING ASSAYS
Binding assays performed at (M^C followed the same protocol as previous assays. The 
cells and all reagents were chilled in an ice-cold water bath to 0-42C. When the cells 
were treated with an acid wash, bound radioactivity (6-8%) was less than non-specific 
values (8-12%) after a 6 hour binding incubation in 125I-NLDP (Figure 3.2.7.). Thus, 
all specific activity was removed from the cells after 6 hours with an acid wash. Hence, 
the tracer was restricted to the cell extemal-cell surface at 0-42C.
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3.2A.2. EFFECTS OF INCUBATION TIMES ON BINDING ASSAYS I
Twenty-four well plates were seeded overnight with 5,4, 3, 2, and 105 cells/well. They 
were then incubated with 1.18xl0-10 M 125I-NLDP for 0.5 and 2 hours (Figure 3.2.8.). 
Cells bound an average of 2.44 times more tracer at 2 hours than at 0.5 hours. Non­
specific binding on the other hand, was higher at 0.5 than at 2 hours. Non-specific 
binding was 14-78.9% of the total bound cpms at 30 minutes, compared to 10.3- 
15.2% at 2 hours. At 2 hours the combined higher specific activity and lower non­
specific binding resulted in a higher specific binding than was observed at 0.5 hours.
3.2.4.3. EFFECTS OF CELL DENSITY ON BINDING ASSAYS
Specific binding increased steadily with both incubation times and cell density at both 
0.5 and 2 hours (Figure 3.2.9.).
Binding assays with over 5x10s cells/well (cell confluence) were not performed. The 
proportionate increase in receptor activity would be counteracted by a decrease in cell 
surface area available for ligand-receptor interaction due to cell clumping. Future work 
was done with 5x10s cells/well. The minimum tracer incubation period was 2 hours.
3.2.4.4. EFFECTS OF PROTEASE INHIBITORS ON BINDING ASSAYS
The effect of 0.3 mM 1,10-phenanthroline on the binding of ,2SI-NLDP to B16 plasma 
membranes was examined. Two binding assays containing 1.24x1 O'10 M 12SI-NLDP 
were run in parallel on B16 over 8 hours (Figure 3.2.10.). One assay contained 0.3 
mM in the binding buffer. The binding profiles were similar. Both binding curves 
gradually rose over time until a maximum binding plateau was reached at 6 hours. 
1,10-phenanthroline was not included in future work as it was not advantageous to 
binding specificity or association times of the free ligand for cell surface binding sites.
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A synthetic collagenase inhibitor (a gift from SmithKline and Beecham) was also 
studied under these binding conditions. Serial dilutions of 10"5, 10~6, and 107 M were 
added to a binding buffer of 2xl0-10 M 12SI-NLDP. B16 cells were incubated in the 
buffer for 8 hours (Figure 3.2.11.). Except for an early plateau (4 hours), the binding 
curves were similar to Figure 3.2.10.. Differences in the amount of bound tracer was 
not consistently altered by inhibitor concentration. The collagenase inhibitor was not 
included in further studies.
3.2.4.5. EFFECTS OF INCUBATION TIMES ON BINDING ASSAYS II
All binding assays up to this point had used approximately 1.18xl0-10 M tracer (157). 
Different concentrations of 125I-NLDP were tested during 0-42C binding assays on 
5x10s cells/well to determine the optimal tracer dilution and incubation time at this cell 
density (Figures 3.2.12. and 3.2.13.).
Figure 3.2.12. displays the binding data for wells simultaneously incubated in 2.7xl0-n 
and 1.08xl0-10 M 125I-NLDP over 20 hours. Both tracer concentrations gave the 0-42C 
binding profile observed previously. There was a rapid increase in bound tracer with a 
small accumulation after 6 hours. Non-specific binding decreased with time at both 
tracer concentrations. It went from 43.7-83.6% at 0.5 hours, to 12.8-11.7% at 22 
hours, for 1.08xl0-10 M and 2.7xlOn M tracer, respectively. In all assays, the 
percentage of non-specific binding decreased over time. Optimal results were obtained 
with a binding buffer incubation over 6 hours.
3.2.4.6. EFFECTS OF 12SI-NLDP CONCENTRATION ON BINDING ASSAYS
Tracer dilution did not alter the percentage of non-specific binding at maximum values 
of total binding. The amount of specific binding was proportional to the dilution of the
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agonist. Four times as much ligand specifically bound 3.2 fold more sites during 
maximum binding.
This trend was not observed when comparing assays performed 3 weeks apart using 3 
different cell passage numbers (A and B, Figure 3.2.13.). During independent binding 
assays, 3.94 fold more specific activity was observed using a binding buffer containing 
1.42 fold more ligand (5.9xl0*n M and 8.38xlO-n M).
A higher tracer concentration shortened binding equilibrium times when assays were 
run simultaneously (Figures 3.2.12. and 3.2.13., A and B assays). A higher tracer 
concentration resulted in more agonist bound when assays were performed 
simultaneously over 6 hours. The specific radioactivity at 6 hours was 64.2 and 59.3%, 
for 1.08xl0-10 and 2.7xl0-n M, respectively. These results are in agreement with the 
Law of Mass Action. An increase in available ligand decreases the time it takes free 
and bound ligand to reach an equilibrium.
This trend was not repeatable when comparing assays performed over a 3 week period 
(Figure 3.2.13., A and B assays). Here a more dilute tracer concentration bound more 
of the total specific activity after 6 hours (5.9xl0*n M, 70%; 8.38xl0-10 M, 57%). Cell 
detachment from the well plates was often observed after 8 hours. Technical 
limitations of tracer production did not make routine assays with tracer concentrations 
above 1.18xl0-10 M feasible. Thus, future work continued to use a binding buffer 
incubation times of 8 hours in approximately 1.18xl0*10 M 125I-NLDP. Occasionally, 
the binding equilibrium was not completely established (the continued accumulation of 
bound ligand after 8 hours at 0-42C) under these conditions.
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3.2.4.7. SATURATION BINDING ISOTHERMS OF 125I-NLDP
B16 murine melanoma were incubated for 8 hours in a 125I-NLDP dilution series of 
103-2xl06 cpm/well. Figure 3.2.14. presents an example saturation binding isotherm. 
Values of bound versus free radio-ligand in a Scatchard Plot allow for the calculations 
of the Ka, Kd, n, and analysis of the receptor population. Figure 3.2.15. displays the 
Scatchard Plot for the raw data in Figure 3.2.14. The 95% regression confidence limits 
are displayed as dotted lines, while its R2 is 0.962 (R2 is the square of the correlation 
coefficient for the regression points). The data was linear confirming the existence of 
one major population of receptors. The points not included in the confidence limits 
were not evaluated as data obtained at these very dilute ligand concentrations are 
highly susceptible to experimental error. Assuming one population of receptors, the 
specific binding isotherm can be described by Equation 2.5.6.1. [HR]/[H] = Ka(n)- 
Ka[HR] (Section 2.5.6.). Estimates of Ka (the slope of the line) and n (the y axis 
intercept/slope) are obtained by fitting the data to Equation 2.5.6.1. using non-linear 
least squares regression analysis. The Kd is calculated as the inverse of Ka. Table
3.2.1. lists the estimates obtained from five replicate saturation binding isotherms.
The values of Ka were in good agreement with standard errors of 10-20%. There was 
more variation in the number of receptors per B16 cell with a mean of 18,022 
(±13,040). This change in receptor number was not surprising considering the 2 year 
period in which these assays were performed. Inherent changes in cellular activity with 
time are frequent. A mean Kd of 4.76xl0-10 M for 125I-NLDP was used during 
calculations of binding affinities of other ligands in competition assays.
Table 3.2.1. The Ka (SD), Kd (SD), n(SD)s for five replicate saturation binding 
isotherms of 125I-NLDP on B16 cells, and their means. The binding (Figure 3.2.14.) 
and Scatchard plots (Figure 3.2.15.) are derived from binding isotherm 2*. All data are 




Ka(109M-!) Kd (10*9 M) n
1 2.09 (±0.19) 0.478 (±0.043) 28,000 (±1400)
2* 1.70 (±0.11) 0.588 (±0.038) 10,100 (±400)
3 1.88 (±0.38) 0.532 (±0.108) 5,900 (±700)
4 2.53 (±0.32) 0.395 (±0.050) 35,700 (±2,500)
5 2.31 (±0.40) 0.433 (±0.075) 10,500 (±1000)
MEAN 2.10 (±0.33) 0.476 (±0.076) 18,040 (±13,022)
3.2.4.8. COMPETTnON ASSAYS
Routine determination of binding affinities for other a-MSH derivatives was 
conducted using competitive binding techniques. A radio-labelled ligand with a known 
binding affinity (125I-NLDP) was incubated for 8 hours at 0-4fiC with 5x10s B16 
cells/well in the presence of various concentrations of unlabelled competitor. Assuming 
the ligands compete for the same receptor (as indicated by the Scatchard Plot), the 
level of non-specific binding is identical for the radio-ligand and its competitor, and 
there is little depletion of ligands in the binding medium, experimental results can be 
described by Equation 2.5.6.2. ( Section 2.5.6.2.):
cpm test = ((cpm max - cpm min) [A]) + cpm min.
[A]+ (KdA) ([B]/KdB)]
Ten replicate experiments were performed with cold (unlabelled) NLDP in competition 
with 125I-NLDP (Table 3.2.2.). The mean dissociation constant for NLDP was 
2.225xl0-9 M (SD ± 0.505xl0-9 M, Table 3.2.3.). This value was used to calculate the 
dissociation constants for radio-ligands other than 125I-NLDP.
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Figure 3.2.16. compares the binding affinities of three separate samples of NLDP. One 
sample was obtained from Sigma Chemical Co.. Another was synthesised by G. Olivier 
in our laboratory. Both preparations were freshly reconstituted in 1 mM HC1. The third 
sample was taken from the second sample but stored in solution for 29 weeks prior to 
use. The relative dissociation constants were 2.13, 2.82, and 2.36xl09 M. There was 
little difference between samples stored for 29 weeks in 1 mM HC1, those newly 
reconstituted, or those obtained from Sigma Chemical Co. All peptide preparations 
were used within 6 months of reconstitution.
Table 3.2.2. lists the dissociation constants (Kd) obtained from individual assays 
together with their standard deviations, at a 95% confidence level, calculated with 
MINSQ non-linear analysis (Section 2.5.6.). A summary for each analogue is presented 
in Table 3.2.3.. This table lists the number of replicate experiments, the mean Kds, 
standard deviations of the means, and the affinities for the a-M SH receptor relative to 
acetylated a-MSH. Figures 3.2.16.-3.2.25. plot an example competition assay/a- 
MSH analogue (data for all assays are listed in Appendix 2).
All probes except for the (Sa-Au)-Bi-125I-NLDP tracer selectively competed with 
NLDP for the a-M SH receptor. The value obtained for the dissociation constant for 
a-MSH was 6.46x1 O'9 M. The value of its NLDP analogue was 2.92 fold less 
(2.22xl0*9 M). Since Kd = 1/Ka, NLDP had a 2.92 fold greater affinity for the a- 
MSH-R than a-MSH. The difference of the means of a —MSH and NLDP was <0.01 
significant, at 95% confidence, using the two-sided Students unpaired T-test. The 
CTAF-NLDP complex was the only probe with a Kd higher than a-MSH. It displayed 
a 7.19 fold loss in receptor affinity at a <0.01 significance level. The addition of 
methotrexate to NLDP resulted in a small decrease in the Kd relative to NLDP (1.14 
fold, <0.05 significance). Biotinylation of the NLDP N-terminus increased the peptides 
binding affinity 6.31 fold (<0.01). The affinities of 125I-NLDP (0.287 significance) or 
Bi-125I-NLDP (0.952 significance) compounds were unaffected when bound with the
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photoaffinity molecule. The addition of streptavidin (Sa) to Bi-NLDP had no observed 
effect on binding affinity (0.376 significance), but caused high non-specific binding 
(data not shown). Conversely, incorporation of the gold-streptavidin complex (Sa-Au) 
to Bi-125I-NLDP removed the ability of the Bi-125I-NLDP to compete with NLDP for 
the a-M SH receptor. Iodination of the NLDP N-terminus resulted in a 4.65 fold 
increase (<0.01 significance) in the ligands affinity for the receptor. Iodination of 
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Figure 3.1. Typical standard curves of a-MSH radio-immunoassays with log pg a -  
MSH/tube plotted against % bound 125I-a-MSH in the presence of unlabelled a -  
MSH/125I-a-MSH bound in the absence of unlabelled a-MSH. Each assay point was 
determined in the presence •  and absence O  of plasma. Points represent the 
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Figure 3.2.1. Total binding/10,000 of 125I-NLDP to B16 cells at 37*C using 1 O  ;
2 #  ; 3 V  I and 4 ▼ washes after binding vrs time. Bars indicate SD values 
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Figure 3.2.2. Binding of 125I-NLDP to B16 cells at 372C in RPMI or PBS buffers with, 
or without, 0.2% BSA vrs time. Binding in RPMI #  ; RPMI with BSA O  ;
PBS T ; PBS with BSA V ; non-specific binding to the wells in RPMI A ; 
RPMI with BSA ■  ; PBS A ; PBS with BSA □  . Points represent the means 
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Figure 3.2.3. Binding of 125I-NLDP to B16 cells at 372C in RPMI or MEM media vrs 
time. Total binding in RPMI □  ; non-specific binding in RPMI ▼ ; specific
binding in RPMI ■  ; total binding in MEM O  ; non-specific binding in MEM 
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Figure 3.2.4. Binding of 125I-NLDP to B16 cells at 37fiC in RPMI with O  ; and 
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Figure 3 .2 .5 .  Total O  ; non-specific V  ; and acid stripped •  ; 125I-NLDP
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Figure 3.2.6. Total O ; non-specific V ; and acid stripped •  ; 125I-NLDP
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Figure 3 .2 .7 .  Total O  ; non-specific #  ; and acid stripped V  ; 125I-NLDP
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Figure 3.2.8. Binding of 125I-NLDP to B16 cells at 0:4eC vrs cell density. Total O  ; 
non-specific □  ; specific V  bound after 0.5 hours; and total ▼ ; non-specific 
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Figure 3.2.9. Binding of 125I-NLDP to B16 cells at 0-49C after 0.5 O  ;and 
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Figure 3.2.10. Binding of 125I-NLDP to B16 cells at 0-4eC in media with O  ; and 
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Figure 3.2.11. Binding of 125I-NLDP to B16 cells at 0-42C in media with 105M O  ; 
106 M #  ; 107 M V ; and no T  collagenase inhibitor vrs time. Points
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Figure 3.2.12. Binding of 125I-NLDP to B16 cells at 0-42C with 1.08xl0-10 M tracer, 
total V  ; non-specific ▼ ; specific O  bound; and 2.7xl0-n M tracer, total 
□  ; non-specific ■  ; and specific #  bound vrs time. Bars represent SD values 
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Figure 3.2.13. Percent maximum bound 125I-NLDP to B16 cells at 0-4sC with tracer 
concentrations of l.OSxlO*10 M T  ; 8.38xlO-n M •  ;5.9xlO-n M O  ; and 
2.7xl0*n M V vrs time. Assays using tracer concentrations of 1.08xlO10 M and 
2.7xl0-n M were performed simultaneously (A), while the other assays (B) were 
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Figure 3.2.14. Saturation binding isotherm of CPM 125I-NLDP bound vrs CPM/10000 
added to each well, using B16 cells at 0-4eC for 8 hours. Total #  ; non-specific V 
; and specific O ; binding of ,25I-NLDP vrs 125I-NLDP added/well. Bars 
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Figure 3.2.15. Scatchard Plot analysis of transformed data from Figure 3.2.14. 
saturation binding isotherm. Bound ,25I-NLDP/free 125I-NLDP vrs bound 125I-NLDP 
molar/cell. The Ka was estimated at 1.7(±0.1 l)xl09 M*1, the Kd was 5.85(±0.38)xl0-10 
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Figure 3.2.16. Competition binding assays of three preparations of NLDP against 
1.25xl0-10 M 125I-NLDP. Percent maximum bound 125I-NLDP vrs unlabelled NLDP. 
Sigma O ; Bath group #  ; 6 month old Bath group V . Respective Kds are 
2.13(±0.057)xlO9 M, 2.82(±0.107)xl()-9 M, and 2.36(±0.113)xl0-9 M. Points 
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Figure 3.2.17. Competition binding assay of a-MSH against 1.42xl0-10 M 125I-NLDP. 
Percent maximum 125I-NLDP bound vrs unlabelled a-MSH. Estimated Kd for a-MSH 
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3.2.18. Competition binding assay of CTAF-NLDP against 1.28xlO*10M 125I-NLDP. 
Percent maximum bound ,25I-NLDP vrs unlabelled CTAF-NLDP. Estimated Kd for 
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3.2.19. Competition binding assay of MTX-NLDP against 1.26xl0-10 M 125I-NLDP. 
Percent maximum bound ,25I-NLDP vrs unlabelled MTX-NLDP. Estimated Kd for 
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Figure 3.2.20. Competition binding assay of Bi-NLDP against 1.2xl0*10 M 125I-NLDP. 
Percent maximum 125I-NLDP bound vrs unlabelled Bi-NLDP. Estimated Kd for Bi- 
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Figure 3.2.21. Competition binding assay of 1.34xl0-10 M Bi-125I-NLDP against 
NLDP. Percent maximum bound Bi-l25I-NLDP vrs- unlabelled NLDP. Estimated Kd 
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Figure 3.2.22. Competition binding assay of 1.43xl0-10 M Bi-125I-ATB-NLDP against 
NLDP. Percent maximum bound lii-l2<iI-ATB-NLDP vrs unlabelled NLDP. Estimated 
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Figure 3.2.23. Competition binding assay of 1.37xlO-10 M 125I-ATB-NLDP against 
NLDP. Percent maximum bound ,25I-ATB-NLDP vrs unlabelled NLDP. Estimated Kd 
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Figure 3.2.24. Competition binding assay of 1.50xl0*10 M (Sa)-Bi-125I-NLDP against 
NLDP. Percent maximum bound (Sa)-Bi-,25I-NLDP vrs unlabelled NLDP. Estimated 
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Figure 3.2.25. Competition binding assay of 1.34xlO-10 M (Sa-Au)-Bi-,25I-NLDP 
against NLDP. Percent maximum Ixnmd (Sa-Au)-Bi-I25I-NLDP vrs unlabelled NLDP. 
There is no estimated Kd for (Sa-Au)-Bi-,25I-NLDP. Bars indicate SD values of 4 
sample wells.
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Table 3.2.2. Dissociation constants (Kd) and their standard deviations (SD) for all 
competition binding assays. Assays 1* are plotted in Figures 3.2.16.-3.2.25. All data 
are listed in Appendix 2.
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Table 3.2.3. The mean of the Kds, the standard deviations of the mean, the number of 
replicate assays, and the relative affinity to a-MSH, are listed for each analogue. The 













NLDP 2.25xl09 5.05x10-1° 2.92 10
a-MSH 6.46x10 9 4.00xl0-9 1.0 4
CTAF-NLDP 4.64xl(H 2.12x10-* 0.139 3
MTX-NLDP 1.54xl0-9 2.01x10-1° 4.19 3
BI-NLDP 3.53x10-1° 1.51x10-1° 18.3 5
125I-NLDP* 4.70x1 O*10 7.60x10-11 13.6 5
BI-,25I-NLDP 5.59x10-1° 1.57x10-1° 11.6 3
BI-125I-ATB-
NLDP 5.50xl0-10 9.41X10-U 11.7 2
125I-ATB-
NLDP 3.76x10-1° 1.94x10-1° 17.2 3
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3.3. TYROSINASE ASSAYS PERFORMED ON B16 CELLS 
TREATED WITH a-MSH ANALOGUES
33.1. INTRODUCTION
Melanoma and melanocytes produce a copper-containing enzyme, tyrosinase. It is 
essential in the biosynthesis of melanin pigment MSH induced melanogenesis occurs 
with an increase in tyrosinase activity (100). Pomerantz (144) developed an assay 
which measured the extent of biological stimulation of pigment cells by hydroxylation 
of [3\5f-3H]-L-tyrosine to 3H20  (144). During this study a modified version of this 
assay (52) was used to evaluate the biological potency of a-M SH analogues.
33.2. TYROSINASE ASSAY DEVELOPMENT
3.3.2.1. EFFECTS OF B16 CELL DENSITY AND INCUBATION TIMES ON 
TYROSINASE ACTIVITY
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The number of B16 mouse melanoma cells/well and incubation times were varied to 
determine the best conditions for tyrosinase stimulation by a-MSH derivatives. Figure
3.3.1. shows the dose-response curves obtained using 24 wells seeded with 105 or 
5x10s cells/well, and incubated for 1 day in a NLDP dilution series. Wells were also 
seeded with 5x10*, 7.5x104, and 3.5x10s cells using a one day incubation time but 
these conditions did not result in comprehensive dose-response curves (data not 
shown). The tyrosinase assay was a better measurement of B16 cell stimulation at 
higher cell densities. These assays also displayed less variation (SD) between sample 
wells. 5x10s cells/well were more responsive to the agonist (Ec50 value of 3.5xl0-12 
M) with less standard deviation than wells seeded with 10s cells/well (Ec50 value of 
3.5xl0-n M). But, the lower cell density (10s cells/well) was deemed more suitable 
since the change in specific response (maximum agonist stimulated 3H20  production) 
was three times greater (3x10s cpm versus 10s cpms) than those wells seeded at a 
higher cell density (5x10s cells/well).
In follow-up experiments, B16 cells were seeded with 10s, 2.5X104, and 5X104 
cells/well. The cells were incubated in a NLDP dilution series for 20, 27, and 43 hours. 
The best results were obtained at 27 hours with 10s cells/well. This was determined by 
the relatively large change in agonist-specific specific response obtained at 27 hours 
when compared to data collected at 20 and 43 hours (Figure 3.3.2., data for 20 and 43 
hours not shown).
The assay was then conducted on cells seeded at a lower cell density for longer 
incubations. Cells seeded at 10s cells/well were incubated for 27 hours, while cells 
seeded at 3X104 cells/well were incubated for 2 and 3 days (Figure 3.3.3.). The largest 
response was obtained with a two day incubation of 3X104 cells/well, although the 
specific change was minimal. The standard deviations of 3H20  production of all three 
protocols were similar (data not shown). The largest differences in the NLDP-specific
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response was obtained at 48 hours. Further tyrosinase assays were performed using a 
two day incubation of the agonist on 3X104 cells/well.
3.3.2.2. PROCEDURE FOR THE EXTRACTION OF UNREACTED [3\5-3H]-L- 
TYROSINE FROM THE ASSAY MEDIUM
The technique used during the charcoal extraction of unreacted P '^ ’^ Hj-L-tyrosine 
from the cell supernatant was examined in an effort to reduce the intrasample variation. 
Supernatant was taken from wells following a 2 day tyrosinase assay of 3X104 
cells/well, containing 1 ml of 109 M NLDP. It was then added to eppendorf tubes 
containing 0.4 mis of ice cold 10% charcoal in PBS. The tubes were agitated on a 
vortex mixer and subjected to one of the following treatments :
1) manually shaken for 15 minutes at room temperature.
2) manually shaken for 15 minutes at room temperature and mechanically
shaken for 15 minutes at 4yC.
3) mechanically shaken for 30 minutes at 42C.
4) and mechanically shaken for 1 hour at 42C.
The smallest intrasample variation was observed at 49C using protocol 3 ( see Table
3.3.1. for standard deviations). In subsequent tyrosinase assays the conditioned 
supernatant and charcoal were mechanically shaken for 30 minutes at 42C.
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Table 3.3.1. The tyrosinase activity and its standard deviations as measured by 
supernatant 3H20  following the four charcoal separation techniques (Section 3.3.2.2.).







3.3.3. TYROSINASE ACTIVITY OF B16 CELLS TREATED WITH a-MSH
ANALOGUES
Estimates of half maximal tyrosinase stimulation (Ec50) of the melanoma cells by the 
peptides were obtained using INSTAT linear regression analysis (Section 2.6.4.) with 
Equation 2.6.4.:
Ec50 = antilog [dpm min + (1/2 x dpm specific - C)/M].
Alpha-MSH and its derivatives were tested over a two year period, using 34 different 
passages of B16 mouse melanoma cells. Figures 3.3.4.-3.3.8. show examples of a 
dose/response curve for each a-MS 11 analogue tested. Data for all assays are listed in 
Appendix 2. Table 3.3.2. lists the estimate of the curve slope (M), its standard error, 
the y-axis intercept (C), its standard error, and the derived Ec50 for each assay. Table
3.3.3. lists the mean Ec50 for each analogue, its standard deviation, its relative potency 
to a-MSH, its efficacy (Kd/Ec50), and the number of replicate assays. The standard 
deviations of the mean for the analogues were low considering they were performed 
with 34 different passages over a 2 year period.
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Most dose/response curves displayed plateaus at non-specific and maximum tyrosinase 
activity. The plateaus were usually separated by a 2-3 log concentration span of the 
experimental peptide. There was olien a drop in activity at ligand concentrations higher 
than those eliciting the maximal hormonal response. Occasionally, the straight line 
portion of the curve would be followed by a rise and fall in tyrosinase stimulation after 
non-specific activity (3H20  produced in the absence of added agonist) had been 
established (Figure 3.3.4.). These effects were not observed consistently throughout 
replicate assays.
The exchange of methionine for norlcucine at position 4, and of D-phenylalanine for 
its L isomer at position 7 (NLDP) caused an 8 fold rise (<0.01 significance) in the 
biological stimulation of B16 cells by the agonist (Table 3.3.3.). Binding of the CTAF 
molecule to NLDP caused a 94 fold drop (<0.01) in tyrosinase activity. The addition of 
a methotrexate molecule to the N-tcrminus of NLDP had relatively little effect (0.668 
significance) on the B16 cellular response. Conversely, biotinylation of NLDP caused 
a 3.4 fold drop (<0.01 significance) in biological stimulation of the cells by the ligand.
The hazards of gamma-radiation did not allow iodinated a-M SH derivatives to be 
lyophilised and weighed. Tracer concentration were determined by cpm after HPLC 
purification (Section 2.5.5.). Each tyrosinase assay required approximately 1.69xl08 
cpms of purified tracer. The yield of radio-ligand after iodination (usually 2xl08) was 
not sufficient for routine tyrosinase assays in triplicate. After purification the 
concentration of iodinated ligand in the HPLC buffer was too dilute for concentrations 
above 10-9 M. During HPLC purification, the tracer was eluted with 49.5-50% 
methanol in 1% TFA HPLC buffer. The TFA and methanol in the HPLC buffer 
would cause cell death at tracer concentrations necessary for tyrosinase assays (10*13- 
107 M). Hence, the a-MSH radio-tracers were not tested for biological activity with 
tyrosinase assays. Photoaffinity compounds were not tested for tyrosinase stimulation
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due to their photo-reactive nature. The light sensitivity of the ATB compound would 
have caused technical difficulties during freeze-drying and experimental manipulations 
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Figure 3.3.1. Tyrosinase activity assay of 105 #  ; and 5x10s O  B16 cells/well in
a NLDP dilution series for 24 hours. H120  production vrs NLDP. Bars indicate SD 
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Figure 3.3.2. Tyrosinase activity assay of 105 V ; 2.5x10s #  ; and 5x10s O
B16 cells/well for 27 hours. :tH20  production vrs NLDP. Points represent the 
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Figure 3.3.3. Tyrosinase activity assay of I05 B16 cells/well for 27 hours O ; 3X104 
B16 cells/well for 48 hours \ 7  ; and 3x10* B16 cells/well for 72 hours 0  ; in
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Figure 3.3.4. Tyrosinase activity of cells incubated in NLDP. Percent maximum 
increase in 3H20  production vrs NLDP. Estimated Ec50 for NLDP is 2.64xl0-n M. 
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Figure 3.3.5. Tyrosinase activity of cells incubated in a-MSH. Percent maximum 
increase in 3H20  production vrs <t MSI I. Estimated Ec50 for a-MSH is 4.25xl0-10 M. 
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Figure 3.3.6. Tyrosinase activity ol cells incubated in CTAF-NLDP. Percent maximum 
increase in 3H20  production vrs (TAF-NLDP. Estimated Ec50 for CTAF-NLDP is 
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Figure 3.3.7. Tyrosinase activily of cells incubated in MTX-NLDP. Percent maximum 
increase in 3H20  production vrs M I X-NLDP. Estimated Ec50 for MTX-NLDP is 
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Figure 3.3.8. Tyrosinase activity of evils incubated in Bi-NLDP. Percent maximum 
increase in 3H20  production vis Iti Nl .1 >l\ Estimated Ec50 for Bi-NLDP is 9.29xl0-n 
M. Bars indicate SD values of A , '  wells.
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Table 3.3.2. The C(SE)s, M(SE)s, and resulting Ec50s, for all tyrosinase assays. Assay 




C(±SE) DPM M(iSE) MOLE-1 Ec50 MOLE
NLDP 1* 91600(16570) 1.00(i2.66)xl010 2.64x10-”
2 119000(14130) 1.29(il.42)xl010 7.78x10-”
3 149000(12780) 4.30(10.95)xl011 6.61x10-”
4 196000(15300) 6.66(115.8)xl09 8.75xl0-12
5 90600(17160) 2.46(i2.35)xl013 1.51x10-”
6 91600(16570) 2.14(122.6)xl09 1.92x10-”
7 65900(14650) 1.83(11.60)xl012 1.55x10-”
8 83900(16110) 2.94(12.10)xl0n 6.66xl0-12
9 54200(15500) 1.86(11.89)xl012 3.06x10-”
10 104000(14250) 1.31(11.38)xl012 9.84xl0-12
a-MSH 1* 50100(194100) 2.55(11.44)xlOn 4.25xl0-10
2 131000(18060) 2.98(12.66)xl010 8.66x10-”
3 115000(196300) 5.43(i21.0)xl09 9.08x10-”
4 70500(14320) 7.60(121.8)xl09 2.87xl0-10
CTAF-NLDP 1* 123000(113000) i . i 5 ( ( i 3 . i 7 ) x i o ” 1.76xl0-10
2 207000(12570) 2.47(18.85)xl09 2.96x10-9
3 131000(16330) 1.60(11.99)xl010 1 2.98xl0-9
4 140000(16150) 1.33(12.1 l)x l010 4.30x10-9
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MTX-NLDP 1* 65800(±5190) 2.50(il.78)xl012 1.72X10-11
2 186000(16030) 2.69(118.0)xl09 2.25X10-11
3 190000(15170) 7.11(115.4)xl09 2.36x10-“
BI-NLDP 1* 184000(15240) 1.97(118.0)xl010 9.29xl0*n
2 138000(15660) 1.79(11.78)xl010 9.70xl0*n
Table 3.3.3. The mean of the Ec50s, the standard deviation of the mean, the relative 
activity to a-MSH, the efficacy determined by Kd/Ec50, and the number of replicate 



























3.4 IN  VITRO GROWTH REGULATION OF B16 CELLS BY cc- 
MSH AND NLDP
3.4.1. INTRODUCTION
Regulation of melanocyte and melanoma growth by a-M SH is a controversial subject 
Some reports observe the inhibition of melanoma growth after exposure to a-MSH, 
whereas others have reported a stimulation of growth or negligible effects (Section 
1.6.2-1.6.3.). Growth curves of B16 mouse melanoma cells in vitro, in the presence 
and absence of a-MSH or NLDP, are described in this section. Melanotropin induced 
growth inhibition was measured by the percent number of treated cells/well compared 
to untreated wells using Equation 2.7. (Section 2.7.).
3.4.2. EFFECTS OF PULSE OR CHRONIC DOSES OF NLDP ON B16 
CELL GROWTH
1 nM NLDP was administered both chronically and for 30 minutes/day (see Section 
2.7.). Figure 3.4.1. shows the effect of NLDP exposure upon B16 cell growth. Chronic 
exposure inhibited cell growth 30% after 3 days and 38% after 4 days. The 30 
minute/day NLDP pulse had no effect on cell growth. Further trials of the chronic 
exposure of B16 cells to NLDP supported these findings (Table 3.4.1.).
Ill
3.4.3. EFFECTS OF a-MSH OR NLDP ON B16 CELL GROWTH
Figure 3.4.2. illustrates the effect of 10-9 M a-M SH and its NLDP analogue on B16 
cell growth. Growth inhibition increased steadily over 4 days when wells were seeded 
with a density of 5x10s cells. Although inhibition was still increasing, it decelerated 
after 3 days. The decline in cell numbers for all wells on day 5 could be due to an 
experimental artefact. Alpha-MSH was less potent than NLDP in inhibiting cell 
growth. This became apparent after a 2 day exposure of the cells to the hormone. 
Wells with 10-9 M a-MSH contained cell numbers between hormone-free, and NLDP 
supplemented wells. An index of cell growth inhibition is listed in Table 3.4.1.
In all experiments, there was a marked alteration in cellular morphology 3-4 days after 
exposure to either a-MSH or NLDP. Cells became highly pigmented and granular, 
and the cell bodies became flattened and dendritic (on visual inspection). Cells 
incubated in a-MSH were less pigmented than those exposed to equal amounts of 
NLDP. It is concluded that under these conditions both a-M SH and NLDP increased 
melanogenesis while decreasing cell proliferation of B16 melanoma.
3.4.4. EFFECTS OF CELL DENSITY AND NLDP TREATMENT TIMES 
ON B16 CELL GROWTH
When wells were seeded at low densities (104, Figure 3.4.3.) the cells displayed typical 
logarithmic growth in the presence or absence of lfr9 M NLDP over 4 days. The 
inhibitory effect of NLDP became more pronounced-after the fourth day as cell density 
increased (5.6x10s cells/well, Table 3.4.1.). When cells were seeded at a high density 
(5x10s cells/well, Figure 3.4.9.), NLDP cell growth inhibition occurred earlier (2 days)
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at a cell density of 9x10s cells/well (Figure 3.4.7., Table 3.4.1.). Wells seeded with, or 
under, 10s cells/well took 5 days to reach maximal inhibition. Those wells seeded with 
over 10s cells took 4 days (Figures 3.4.1., and 3.4.4-3.4.9.). NLPD induced growth 
inhibition gradually increased over time regardless of cell density, until a stationary 
phase of growth was reached. NLDP induced growth inhibition was influenced by cell 
density and length of chronic exposure.
3.4.5. EFFECTS OF NLDP DOSE CONCENTRATION ON B16 CELL 
GROWTH
Growth inhibition by chronic doses of NLDP was concentration-dependent. lfr7 M 
NLDP induced 34% cell growth inhibition after a five day exposure (Figure 3.4.10., 
Table 3.4.1.). A similar result was observed at concentrations below 10-9 M but the 
effect was diminished. B16 cell growth inhibition by NLDP increased most markedly 
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Figure 3.4.1. The effect of 1 nM NLDP doses of chronic ^7  * pulse O ; and
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Figure 3.4.2. The effect of chronic doses of 1 nM NLDP 0  ; a-M SH ; and 
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Figure 3.4.3. The effect of a chronic dose of 1 nM NLDP #  ; and no treatment 
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Figure 3.4.4. The effect of a chronic dose of 1 nM NLDP #  ; and no treatment 
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Figure 3.4.5. The effect of a chronic dose of 1 nM NLDP #  ; and no treatment
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Figure 3.4.6. The effect of a chronic dose of 1 nM NLDP #  ; and no treatment
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Figure 3.4.7. The effect of a chronic dose of 1 nM NLDP #  ; and no treatment
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Figure 3.4.8. The effect of a chronic dose of 1 nM NLDP #  ; and no treatment
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Figure 3.4.9. The effect of a chronic dose of 1 nM NLDP #  ; and no treatment 











1 4 0 0 0 0 0
1200000
1000000
8 0 0 0 0 0
6 0 0 0 0 0
4 0 0 0 0 0
200000
0
1 0 0  1 2 0  1 4 08 06 00 20 4 0
TIME (HRS)
Figure 3 . 4 .10. The effect of a chronic dose of 107 M O  ;10-8M V  ;10-9M 
#  ; 10-n M ▼ ; and no treatment □  on 7X104 B16 cells/well vrs time. Points 
represent the means of 4  sample wells.
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Table 3.4.1. Percent melanotropin induced growth inhibition relative to untreated cells 
over time. All data are listed in Appendix 2.
FIGURE DAYS

























3.4.3. 2.35 20.0 14.8 30.2 28.3 28.0
3.4.4 18.9 7.14 8.89 33.4 45.0 45.4
3.4.5. 0 7.14 12.5 24.6 34.4 41.2
3.4.6. -14.4 2.82 19.5 37.7 43.9
3.4.7. -16.3 13.2 12.1 29.8 32.9
3.4.8. 19.5 -4.17 31.9 48.8 43.2





























4.1. POTENTIAL FOR MSH AS A CARRIER DURING SITE- 
SELECTIVE DRUG DELIVERY
The purpose of drug targeting is to reduce toxic side effects and increase the therapeutic 
index of the drug. Pharmaceutical and biological considerations demand that the ideal drug 
carrier should : 1) be biodegradable; 2) be non-immunogenic 3) be non-toxic; 4) be 
selectively delivered; 5) have a high carrier capacity; 6) be able to control the release of 
the drug; 7) have low production costs; 8) have reproducible properties; and 9) have a 
good shelf-life (5). In an effort to meet these criteria, drugs have been linked to a variety 
of carriers such as antibodies, glycoproteins, lectins, DNA, liposomes, and hormones. 
Hormones may be preferred since they are: 1) relatively easy to obtain in chemically pure 
form: 2) are not bound by Fc receptors on macrophages; and 3) do not cause allergic 
responses since hormones are structurally similar or identical in different species (188). 
Several toxins are extremely lethal at very low doses. These compounds are suited for 
targeted-delivery since their high potency enables effective dose concentrations to be low. 
A site-specific hormone conjugated to a potent toxin would need minimal amounts 
administered to the patient for cytotoxicity of the targeted cells. If the hormone bound 
selectively to its receptor with very little non-specific binding, and its receptor was only 
available at the target site, a high therapeutic index could be achieved. A hormone that 
exerts its effect merely by binding to a cell surface receptor is unlikely to be a good site- 
specific drug carrier. After binding, the receptor must mediate entry of the conjugate into 
the cell's interior in order for the toxin to exert its cytotoxic effect The internalisation of a
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hormone-receptor complex could be associated with intracellular activity and possible 
desensitisation of receptor binding.
One hormone being investigated as a drug carrier is alpha-melanocyte-stimulating 
hormone (a-MSH). Its receptors are found most frequently on melanocytes and 
melanoma cells. MSH related compounds could eventually serve as pharmaceuticals for 
clinical application in : 1) the treatment of pigment disorders; 2) treatment of certain forms 
of dementia; 3) the enhancement of nerve-regeneration and protection from nerve damage; 
4) the control of fever and inflammation; and 5) diagnosis and therapy of melanoma (52). 
Although a-M SH receptors (MSH-Rs) are expressed in both melanoma and non-cancer 
pigment cells, killing of these non-cancer cells with drug-MSH conjugates is considered 
tolerable since only non-fatal de-pigmentation should occur. This study addresses the 
application of MSH in site-selective drug or probe delivery to, and within, melanoma cells.
The MSH analogue [Nle4J)-Phe7]-a-M SH (NLDP) is well suited as a targeting molecule 
for delivering therapeutic or imaging agents selectively to the a-MSH-R. It: 1) is 
biodegradable; 2) is non-immunogenic; 3) has no toxic side-effects when administered to 
mice as 2 mg/kg daily over four weeks; 4) can be used in transdermal drug delivery as 
NLDP diffuses reproducibly across mouse skin (45); 5) has a high specific affinity for the 
a-MSH-R resulting in prolonged cellular activation; 6) has a chemical structure which 
allows labels, toxins, and other compounds to be attached without compromising either its 
binding or stimulatory properties; 7) can be manufactured in mg quantities on a 
peptide synthesiser ; 8) has been well-characterised by several investigators; and 9) is 
stable for several years when suitably stored below (FC.
Use of MSH as a vector in site-specific delivery requires more knowledge of its binding 
characteristics and its biological fate following binding. In an attempt to describe the
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MSH/receptor interaction, the possible internalisation of the ligand-MSH-R complex or its 
separate elements, and its (their) metabolic fate, the group at Bath have synthesised and 
tested a number of melanotropic conjugates which have a selective affinity for MSH 
receptors. Several of these stimulate biological activity in a dose-dependent manner in B16 
melanoma cells. They were used to: monitor, target toxins to, and extract the a-M SH 
receptor found in monolayers of B16 murine melanoma.
4.2. BINDING OF *25i-NLDP TO a-MSH RECEPTORS OF B16 
CELLS
Binding assays and tyrosinase assays were developed to measure the potential of various 
a-M SH derivatives as tools in the study and treatment of melanoma. Determination of 
endogenous a-M SH in the B16 melanoma growth media was undetectable (radio­
immunoassay for a-MSH, Section 3.1.). Thus, all results were attributed to 
experimentally added a-MSH.
125I-NLDP binding assays were performed on B16 monolayers in RPMI 1640 media 
containing 0.2% BSA. The time required for a relative equilibration of the tracer with the 
MSH-R at 0-4®C was longer than that observed by other investigators. Maximum binding 
was achieved on B16 murine melanoma monolayers by Siegrist et al (157) at 6, 3, and 0.5 
hours at 4, 15, and 37CC, respectively. Our assays took 8, 6, and 1 hours to reach 
maximum binding at the same temperatures. The longer equilibrium times could be due to 
the secretion of protein endopeptidases by the melanoma cells during the assay (42). These 
peptidases could prolong the binding times of tracers to the MSH-R by continually 
degrading the ligand during the binding incubation. At 0-4*C there was a 2 hour difference
127
between our relative equilibrium binding times to those of Siegrist et al (157). Protein 
endopeptidase secretion were not expected to be responsible for ligand degradation at 
these temperatures as cells were not metabolically active. Preliminary binding experiments 
with the protease inhibitor 1,10-phenanthroline and a collagenase inhibitor had little effect 
on the binding of 125I-NLDP to B16 melanoma. Either enzymatic degradation was not 
involved during receptor-binding incubations, or the collagenase inhibitor and 1,10- 
phenanthroline were unable to inhibit enzymatic degradation of the tracer. The variation in 
binding times could be due to the use of different B16 subclones, and/or a difference in 
experimental procedure not described in journal articles.
The minimal amount of acid-resistant ligand (7%), and the low non-specific binding (12%) 
of 125I-NLDP (Section 3.2.4.5.) to a-MSH-Rs of B16 melanoma at 0-4cC, allowed for 
the calculation of affinity constants of other a-M SH derivatives when competed with 125I- 
NLDP (Section 3.2.4.8.). The assumption is made that if 125I-NLDP is limited to external 
receptors of the plasma membrane, so are other a-M SH analogues.
4.3. CHARACTERISATION OF THE a-MSH RECEPTOR OF B16 
CELLS
Scatchard plot analysis of saturation binding isotherms suggested a single a-MSH-R 
population with a mean of 18,022 (±13,022) receptors per B16 cell These results are in 
agreement with receptor numbers observed by other investigators. B16 are quoted to have 
9,570 (156), 2,805 (176), and 683-10,000 receptors/cell depending on the B16 sub-clone 
and growth media (167). In B16 tumours there were an estimated 14,700 receptors/cell
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(159). Solca et al (166) estimated 20,000 a-MSH-Rs per B16-F1 cell using a 
photoaffinity Naps-NLDP tracer.
Studies with photoaffinity labels describe the a-M SH-R of B16 cells as a single 
population of 41-46 kDa, often composed of two proteins possibly representing two 
receptor moieties with one binding site (1, 152, 158, 167). Recently molecular cDNA 
techniques showed the MSH receptor of Cloudman murine melanoma, WM 266-4 human 
melanoma, and cervical cancer cells to be 34.795-35 kDa, 297, 317, and 361 amino acids 
long. It has a glycosylated N-terminal containing 7 membrane-spanning sequences, that 
bind GTPs proteins when activated (38,62,126).
4.4. STRUCTURE/FUNCTION ASPECTS OF a-MSH PROBES AND 
TOXIN FOR THE a-MSH-RECEPTOR OF B16 CELLS
4.4.1. a-M SH  AND NLDP
The estimate for the dissociation constant (Kd) of NLDP was obtained by competition 
assays with 125I-NLDP. It was 2.92 fold lower than the value observed for a-M SH. The 
biological potency of NLDP (Ec50) was measured with tyrosinase assays. It was 8 fold 
greater than the estimate observed for a-M SH. NLDP had a Kd of 2.22xl0-9 M and an 
Ec50 value of 2.76xl0-n M for receptors of B16 murine melanoma. The corresponding 
a-M SH parameters were estimated to be 6.46xl0-9 M and 2.22xl0'10 M, respectively. 
These results are in accordance with Kd and Ec50 values for NLDP and a-M SH 
published by other researchers. Other studies reported NLDP to have a 6 fold greater
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affinity for the a-M SH-R than a-M SH. Melanotropin receptors on B16 melanoma cells 
displayed a Kd of 3.2xl0-10 M for NLDP compared to the Kd of 1.9x1 O'9 M for a-M SH 
(156). Siegrist (161) has observed a variation of a-MSH Kd values of 1.31-2.6xlO-9M for 
different B16 sub-clones. Tyrosinase assays of a-M SH and NLDP on Cloudman mouse 
melanoma gave Ec50 estimates of 2.0-5.4xl0-9M and 2.8xl0-n M, receptively (127, 150, 
202).
In a-M SH the replacement of Met by Nle at position 4 and D-Phe for its L enantiomer at 
position 7 produced a stereo structural analogue [Nle4 JD-Phe7]-a-M SH (NLDP) which:
1) maintained its binding and biological activities after iodination with chloramine T; 2) 
resisted enzymatic degradation by serum enzymes; 3) had a high affinity for the MSH 
receptor; and 4) displayed potent and prolonged biological stimulation as measured by 
raised tyrosinase levels (120,150,158).
4.4.2. ^ -N L D P  PROBE
Radio-labelled NLDP, 125I-Tyr2-NLDP (125I-NLDP) displayed a high specific affinity for 
various human and mouse melanoma. The tracers affinity was similar to its unlabelled form 
when iodinated according to the equimolar chloramine T procedure. Conversely, 
iodination of a-M SH with chloramine T produced a tracer with 50% the activity of 
unlabelled a-M SH (53). This is thought to be due to the oxidation of the Met4 residue 
during iodination. The a —MSH sequence 4-9 -Met4-Glu5-His6-Phe7-Arg8-Trp9- stimulates 
bioactivation and is particularly vulnerable to changes in the structure of the Met residue. 
The oxidation of the Met residue of a-M SH represents a mechanism for its inactivation in 
vivo (157). Replacement of Met4 by norleucine increased the ability of the peptide to
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induce cellular activation by 62.5% (157). The C-terminal 10-13 -Gly,0-Lysn -Pro12-Val13- 
NH2 of a-M SH potentiates the cellular response. The D-Phe residue at position 7 could 
protect the peptide from chemical degradation (51).
Iodination of NLDP increased the affinity of the peptide for its receptor 4.65 fold. 
Conversely, the binding affinity of Bi-NLDP (Section 4.4.4.) was not affected by 
iodination. Other researchers have found iodination of the Tyr2 of melanotropins to have 
little effect on the peptide's affinity for the MSH-R. The binding affinity of unlabelled a -  
MSH was 1.9xl0-9 M and 1.3xl09 M after iodination to the [3'-Iodo-Tyr2]-a-M SH 
analogue (49). The increase in the NLDP affinity following iodination could be due to an 
increase of the peptides hydrophobicity or experimental variability. All iodinated a-M SH 
and photoaffinity analogues were not examined for cellular stimulation with tyrosinase 
assays as explained in Section 3.3.2.2.
When designing tools for studies and possible therapy of melanoma, it was necessary to 
use a carrier that would: 1) have a high affinity for the a-M SH-R with low non-specific 
binding; 2) stimulate a biological response, hence possible internalisation of the ligand-a- 
MSH-R complex or its subunits; and 3) retain the above characteristics after iodination. 
Consequently, the NLDP carrier peptide was used instead of a-M SH when designing 
melanotropin-probes and toxins.
Conjugates of a-M SH generally maintained a high degree of biological activity when the 
hormone was attached to additional groups via its N-terminal. The C-terminal was less 
tolerant than the N-terminal. Eberle claims (52) it must consist of a basic side-chain at 
position 11 and a conformational stabilising element at position 12. Our studies of an 
alanine scan of a-MSH (postgraduate work in progress) has shown the replacement of 
Lys11 with alanine has no effect on binding or bioactivity of the peptide. The presence of a
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residue at position 13 was not essential for biological activity (50). Chaturvedi et al (36) 
found the N-terminal Ser^Tyr^Ser3- sequence of NLDP was not essential for the 
retention of biological activity. Hence, all melanotropin-probes or toxins used in this study 
were attached to the N-terminus of NLDP.
4.4.3. CTAF-NLDP PROBE
Addition of the large CTAF molecule to NLDP at its N-terminus lowered the binding 
affinity of the agonist 20 fold, raising the Kd value to 4.64x10* M. This was reflected 
in a 94 fold drop in relative tyrosinase activity (Ec50 2.6xl09 M). These results were 
expected since an increase in the size of an a-M SH analogue or a blockage of the peptide 
at its N-terminus with bulky groups, reduces its activity 2-10 fold in the first instance and 
400 fold in the second (52). The CTAF molecule may sterically interfere with the binding 
sequence of NLDP to the a-MSH-R, its subsequent internalisation, and internal 
signalling (tyrosinase expression). Alternatively, the CTAF-NLDP probe prepared in our 
laboratory may be too large for an easy access into the melanoma cytosol via the a-M SH- 
R.
4.4.4. BI-NLDP PROBES
Biotinylation of NLDP at its N-terminus increased its affinity for the a-M SH-R 6.31 fold 
in our binding assays. The Kd value for Bi-NLDP was 3.53X10-10 M. The reverse was 
observed in tyrosinase assays showing a 3.4 fold drop in the cellular response of B16 cells
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to Bi-NLDP with an Ec50 estimation of 9.5xl0-n M  Eberle (52) found the biological 
activity of an a-M SH analogue would drop 2-10 fold if the lipophilicity of the peptide 
was increased. The hydrophobic properties of the biotin label could increase the affinity of 
an attached melanotropin for its receptor by bringing it in closer proximity to the a-M SH- 
R located in the lipoprotein bilayer of the plasma membrane. By the same mechanism, the 
label may then interfere with receptor-mediated internalisation of the receptor-ligand 
complex into the hydrophilic cytosol
Neither iodination, the addition of the 4-(l-Azi-2,2,2-trifluoroethyl)benzoate (ATB) 
photoaffinity label or streptavidin interfered with the binding of Bi-NLDP to the a —MSH- 
R. Conversely, the incorporation of the gold (10 nm)-streptavidin complex in Bi-125I- 
NLDP removed the ability of the probe to compete with NLDP for the a-M SH-R. This 
result could be interpreted as the probe losing its ability to bind to the a-M SH-R, or a 
high level of non-specific binding masking a specific effect The reduced binding properties 
of the agonist might be caused by steric hindrance of the gold-streptavidin compound 
physically interfering with the binding domains of NLDP. Distancing the Sa-Au marker 
from NLDP with a linker might restore binding to the new (Sa-Au)-Bi-linker-125I-NLDP 
probe. It would be interesting to insert a peptide linker between NLDP and the gold- 
streptavidin complex (Sa-Au) to test this hypothesis.
4.4.5. ATB-NLDP PHOTOAFFINITY PROBES
There was no change in the binding affinities when tracers 125I-NLDP and Bi-125I-NLDP 
were coupled with ATB to form 125I-ATB-NLDP and Bi-125I-ATB-NLDP, respectively. 
Incorporation of the ATB label into the NLDP molecule at the Lys11 residue did not effect 
the binding properties of the agonist These results are in agreement with our observation
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that position 11 of a-M SH peptide can be exchanged for a neutral amide with no side 
chains, without a change in binding affinity or bioactivity of the ligand. Therefor, 
attachment of the ATB label to the Lys11 residue of NLDP did not interfere with the 
interaction of NLDP for the a-MSH-R and its subsequent cellular activity.
4.4.6. MTX-NLDP TOXIN
Addition of methotrexate (MTX) at the N-terminus of NLDP did not alter the peptide’s 
affinity for the a-M SH-R, or interfere with its stimulation of the cell. The Kd and Ec50 of 
the MTX-NLDP conjugate were 1.54xl0-9 M and 2.11xl0-n M. These values compare 
with the values observed for NLDP at 2.25xl0-9 M and 2.76xl0-n M, respectively.
4.4.7. EFFICACY OF a-M SH  PROBES AND TOXIN
In all cases, the tyrosinase Ec50 of B16 melanoma occurred at a lower concentration of 
the a-M SH analogues than was required for half maximum receptor binding. For all 
compounds tested in this study, the Ec50 estimates were consistently lower than their Kd 
values. The increase in sensitivity from binding to cellular activity was: 29 fold for a -  
MSH; 81 fold for NLDP; 18 fold for CTAF-NLDP; 3.7 fold for Bi-NLDP; and 73 fold for 
MTX-NLDP. As previously reported, the NLDP analogue was the most potent in eliciting 
a cellular response (120,150). It was 12 fold more potent than a-M SH in B16 melanoma 
tyrosinase assays. This increase is thought to be caused by the prolonged binding of NLDP 
to the a-M SH-R with conformational properties related to the exchange of L-Phe7 for D-
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Phe7 which stabilise the interaction. The loss of potency with the addition of the CTAF 
and Biotin labels to NLDP, could be caused by their hydrophobic properties or in the case 
of CTAF, its size.
This amplification of a cellular response as a consequence of agonist-receptor interactions 
is typical for a receptor that utilises stimulatory G proteins (guanine nucleotide-dependent 
regulatory proteins) as second messengers. G protein coupled receptors bind GDP 
(guanine diphosphate) by their a-subunits during their inactive state. Once activated, they 
exchange the GDP molecule for GTP (guanine triphosphate) and release of the G TP-a- 
subunit which regulates the activity of adenylate cyclase. Hydrolysis of the bound GTP to 
GDP by the a-subunit terminates the G protein signal (204). Amplification of an internal 
signal occurs as a single occupied MSH-R activates several Gs proteins which lead to a 
biological response. Additional specificity of a receptor effected event could be achieved 
with MSH-R-specific Gs proteins during MSH transmembrane signalling. G proteins also 
allow cells to respond rapidly to very low concentrations of extra-cellular stimuli (178). 
The low endogenous concentrations of MSH in the body (undetectabe-1 pM) suit this 
model. The functional coupling of a stimulatory G protein (Gs) to the MSH-Ris suggested 
by the code sequence of the cloned MSH-R, although this is not conclusive evidence. The 
high efficacy observed with the a-M SH analogues is probably due to a Gs regulatory 
mechanism employed by the a-MSH-R.
In our study, tyrosinase assays produced data with standard deviations of up to 40% (% 
maximum tyrosinase increase above basal levels) for replicate samples. Variations in 
experimental times, cell density, and techniques for the removal of unreacted [3 '^'-3H]-L- 
tyrosine could not eliminate this deviation. The Tyrosine Hydroxylase assay could be an 
improvement on the tyrosine assay employed in this study. The Tyrosine Hydroxylase 
assay uses L-[carboxy-,4CJtyrosine as the substrate, and releases MC 02 upon stimulation
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of tyrosinase (200). Better measurements of MSH-related biological activity might be 
obtained with other in vitro biological assays such as the; In situ melanin (155), adenylate 
cyclase, and cAMP assays (63). Other researchers have found these assays to produce 
more accurate data than was observed in our tyrosinase assays (52).
4.5. RADIO-IMAGING OF MSH RECEPTORS OF MELANOMA 
CELLS USING MSH PROBES
Recently, the melanotropic tracer 125I-NLDP was useful in quantifying MSH receptors of 
B16-F1 mouse melanoma tumours with auto-radiography (159). MSH tracers have also 
elucidated the distribution of MSH receptors in rodents (47, 175). Although the radio- 
signal was greater in melanoma tumours, its distribution was extensive. This is probably 
due to the pleiotropic nature of a-M SH.
Clinical targeting of human melanoma was achieved with a novel chelating a-M SH 
derivative (bisMSH-DTPA) which binds in indium firmly. Bard et al (9, 10) observed 
specific targeting of the compound to Cloudman melanoma in vivo. ,n In-bis-MSH-DTPA 
was successful in the diagnosis of 89% of melanoma lesions in 15 patients (201).
During our studies, Scatchard plot analysis of ,25I-NLDP binding isotherms gave a 
dissociation constant (Kd) of 4.76xl0-10 M for a-M SH receptors on B16 mouse 
melanoma. Tatro et al (176) estimated the tracer to have a Kd an order of magnitude 
lower (5xl0-n M) for receptors of B16-F10 C23 melanoma. It is difficult to evaluate our 
results for 125I-NLDP when so few Kd values of 125I-NLDP have been published by other
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researchers. Our tracer 125I-NLDP appears to be suitable for localisation studies of the a -  
MSH-R on B16 melanoma cells in vitro.
4.6. POSSIBLE RECEPTOR-MEDIATED INTERNALISATION OF 
MSH PROBES BY MELANOMA CELLS
As previewed in Section 1.6.5., internalisation of plasma membrane MSH-R-ligand 
complexes is thought to occur after binding of an a-MSH agonist Binding experiments of 
metabolically active melanoma with fluorescent, ferritin-labelled, or iodinated probes in 
combination with pulse-chase and acid wash treatments, have presented evidence for the 
internalisation of both human and mouse MSH-R-ligand complexes (43, 102, 158, 183, 
184,185). Further evidence for internalisation of the MSH-R-ligand was supported by the 
temperature and time-dependent association of 125I-f$-MSH with internal binding sites of 
Cloudman melanoma cells (132).
Orlow et al (132) observed specific internal binding sites for 125I-|$-MSH within the 
Cloudman melanoma cytosol after binding of the tracer at 12SC, followed by a 15 minute 
incubation at 37fiC. Further studies showed these sites to be associated with a 50% 
sucrose gradient layer. These internal sites were of identical molecular weight (50-53 
kDa), and shared common antigenic determinants with 125I-P~MSH binding sites on the 
melanoma cell surface. Variant melanoma cells which differed from the wild-type with a 
lowered cellular response to (3-MSH (changes in tyrosinase levels, dopa oxidase, and 
dopachrome conversion factor activities, melaninsation, proliferation, and morphology), 
had fewer internal binding sites, even though their ability to bind MSH on the outer cell
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surface appeared normal. Thus, internal binding sites are thought to be involved during 
cellular responses to MSH.
In our studies, internalisation of the MSH-R-ligand was measured by the radiation 
associated with melanoma cells after an acid wash treatment. This treatment removes 
external cell-surface receptor-bound ligand (Section 1.6.5.). At 0-42C, acid-resistant 
accumulation of 125I-NLDP did not go above non-specific levels (Section 3.2.4.1.). The 
binding pattern of 12SI-NLDP to the B16 melanoma cell surface with possible internal 
binding sites (as determined by acid wash treatments) was similar to studies by researchers 
claiming internalisation of the MSH-R-ligand complex by melanoma cells. In all cases 
(including this study), the MSH probe was bound at 0-42C, but was not observed 
intracellularly.
When the binding assay was performed at increased temperatures, the tracer accumulated 
in the cytosol. At 152C, there was a steady increase in acid-resistant tracer over 25 hours, 
reaching a maximum of 42.1% of the total tracer bound (Section 3.2.3.). After 1 hour at 
372C, intracellular tracer reached a maximum plateau of 26-33.2% (Section 3.2.2.4.). 
Both cell-surface associated and acid resistant 12SI-NLDP reached maximum levels 
concurrently (1 hour at 37fiC). There was a rapid rate of 125I-NLDP dissociation from the 
cell surface once maximum binding was achieved, while intracellular levels remained stable 
(Section 3.2.2.4.). Similar results have been observed by other researchers also using the 
B16 murine melanoma system (Section 1.6.5.; 52,133,158).
The decline in surface binding of the a-M SH-R at 372C may be influenced by a number of 
processes: 1) the temporary loss of receptor sites after ligand-stimulated receptor 
internalisation; 2) the loss of receptors due to lysosomal degradation; 3) recycling of the 
receptor back to the cell surface after dissociation of the ligand in an inactive state; 4)
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down-rcgulation of the receptor (with the possible involvement of 1-3); and 5) release of 
the ligand either degraded or whole, back into the incubation medium. Siegrist et al (158) 
claimed that degradation of the MSH tracers by proteases in the incubation media caused 
the observed dissociation of the ligand from the melanoma cell plasma membrane (Section
4.2.). These questions could be addressed with the development of a-M SH probes in 
conjunction with microscopic technologies (light, fluorescent, confocal, and electron 
microscopy), and/or sub-cellular fractionation studies. In summary, the 125I-NLDP tracer 
has a reproducibly high affinity for the a-M SH-R with low non-specific binding to B16 
melanoma cells in vitro. After binding of an agonist, it appears to be transported with the 
a-M SH-R during intracellular cycling. These attributes make ,25I-NLDP a suitable probe 
for identifing the a-M SH receptor of B16 melanoma cells with potential use in future 
localisation and internalisation studies.
4.7. USE OF FLUORESCENT-MSH PROBES DURING STUDIES 
OF MSH RECEPTORS OF MELANOMA CELLS
The internalisation pathway of the MSH-R-ligand complex has yet to be explored with a 
sensitive fluorescent marker. Consequently, the fluorescent derivative Na-((chlorotriazin- 
2-yl)amino)fluorescein-[Nle4JD-Phe7]-a-M SH was synthesised in our laboratory by 
attachment of the CTAF molecule to the N-terminal of NLDP ( synthesised by Dr. George 
Olivier). The probe was tested for selective binding and cellular activation of the a-M SH- 
R of B16 melanoma cells. The CTAF-NLDP probe was determined to have specific 
binding and elicit a specific cellular response of the MSH-R of B16 cells. Thus, it is a 
candidate for monitoring the binding and subsequent intracellular route of receptor-bound 
agonists with light, electron, fluorescent, and confocal microscopy.
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The localisation of fluorescein isothiocyanate-labeUed-^-MSH (FlTC-fV-MSH) molecules 
in internal vesicles of melanoma has helped describe the possible internalisation pathway 
for a-M SH using a fluorescent marker (184, 185). Binding and biological activity of this 
compound were not characterised.
DiPasqual et al (43) synthesised a biologically active a-MSH-feiritin-HTC complex and 
which displayed specific labelling of receptors in the plasma membrane of Goudman 
mouse melanoma, at both the fluorescent and electron microscopic levels. Its binding 
affinity was 7.7xl0-10 M with a biological activity one third that of a —MSH during 
tyrosinase assays. Only 10-20% of the cells showed a patchy significant fluorescence when 
incubated with the a-MSH-ferritin-FITC probe. It is unknown if it was internalised as the 
cells were incubated with the probe at metabolically inactive temperatures (0-4cC). The 
patchy localisation of receptors on the melanoma cell surface could have been associated 
with developing clathrin-coated pits. The CTAF-NLDP probe examined in this study had a 
50 fold lower affinity for the a-MSH-R than this MSH-ferritin-FTTC probe.
Chaturvedi et al (37) prepared a fluorescein-labelled melanotropin [N“- 
((chlorotriazmyl)amino)fiuorescein-Ser1,Nle4,D-Phe7]-a-M SH (CTAF-NLDP) using the 
NLDP agonist as the parent peptide. The fluorescein analogue was as potent as a-M SH 
in stimulating tyrosinase expression. Its binding affinity for the a-M SH  receptor was not 
examined.
Wunderlin et al (202) constructed an a-melanotropin/tobacco mosaic virus disulphide 
(TMV-SS-a-MSH) conjugate with roughly 333 disulphide-liked a-M SH molecules per 
viron, as well as approximately 200 rhodamine molecules per viron. Its affinity for the a -  
MSH-R was 2-6 times higher than a-M SH, and had the same biological activity of NLDP
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(7.52xl0-10 M). As with the a-MSH-femtin-FITC label, its binding was limited to 20- 
40% of the cells. They claimed 40% of the bound complex was internalised following a 30 
minute incubation at 37fiC. They were able to show a time-dependent accumulation of the 
TMV-a-MSH conjugate within the cell, but it could not be accredited to a localised area 
or organelle type. Our CTAF-NLDP probe was 3.37 fold less able to stimulate tyrosinase 
expression (Ec50 value of 2.6xl0*9 M) than the TMV-SS-a-MSH conjugate. Its binding 
affinity for the a-M SH-R was a log cycle lower (4.64x10-® M) than both the above 
mentioned melanotropin-fluorescent conjugates.
Considering the low a-M SH-R numbers observed on mouse (683-20,000) and human 
(400-2,000) melanoma cells, and the poor resolution given by fluorescent markers, the use 
of fluorescent probes may not be the optimal approach for mapping the intracellular route 
of the MSH-R and its agonists. Preliminary experiments with our CTAF-NLDP probe in 
localisation studies of the a-MSH pathway with flow cytometry were not encouraging. 
The signal was too weak and diffuse throughout the B16 melanoma cell for any specific 
binding to be recognised (postgraduate work in progress). Due to: a reduced binding 
affinity, reduced biological activity, and minimal visual localisation of the fluorescent 
signal; our CTAF-NLDP conjugate is not an improvement on existing fluorescent- 
melanotropin probes. Augmentation of the label could make future fluorescent-MSH 
probes more successful in monitoring the MSH-R cell cycle. This could be achieved by 
increasing the carrying capacity of the melanotropin via the strepavidin-biotin mechanism. 
There are 4 biotin binding sites for each streptavidin molecule (75). Combining a 
biotinylated-CTAF label with a (Sa)-Bi- NLDP peptide would increase the fluorescent 
label : peptide ratio from 1 : 1 (as for the CTAF-NLDP conjugate) to 4 : 1 with a 
maximum of 4 labels per receptor.
141
4.8. USE OF BIOTINYLATED-MSH PROBES DURING STUDIES OF 
MSH RECEPTORS OF MELANOMA CELLS
There are additional labels which allow the visualisation of the MSH-R besides MSH-radio 
ligands and MSH-fluorescent markers. Some of these are biotinylated compounds, and 
chemical (Section 4.1.) or photoaffinity labels. The biotin molecule is especially promising 
as a marker since the avidin-biotin system can be used to construct sensitive methods for 
the visual localisation of the MSH-R on/or within melanoma cells, at both the light and 
electron microscopic levels.
Chaturvedi et al (36) found that biotinylated NLDP equalled a-M SH in tyrosinase assays. 
The affinity of Chaturvedi's biotin-MSH probe was not calculated. A biotinylated 
derivative of ACTHM7 has been synthesised and biologically characterised (7). A 
dissociation constant of 1.67xl09 M was determined with competition binding assays on 
mouse B16-F1 melanoma.. Our synthesis of Bi-NLDP followed the protocol of 
Chaturvedi et al (36). Both of the probes Bi-NLDP and Bi-125I-NLDP developed by Dr. 
George Olivier displayed a 3 fold greater affinity for the a-MSH-R than the Bi-ACTHM7 
derivative, with observed Kds of 3 .5xl010 M and 5.5xl0-10 M, respectively. Ours is the 
first report of the application of a biotinylated-melanotropin probe to receptor studies on 
melanoma cells.
In an effort to both amplify and increase the resolution of the biotin signal at the 
ultrastructural level, the (Sa)-Bi-125I-NLDP and (Sa-Au)-Bi-125I-NLDP probes were 
constructed. The addition of streptavidin did not alter the affinity of the molecule, while 
the addition of the 10 nm gold marker completely inhibited specific binding of the (Sa)-Bi-
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125I-NLDP tracer. These results demonstrate that Bi-NLDP and its related derivatives (not 
containing gold markers), are useful tools during MSH-R microscopic studies of receptor 
targeting. This area of research has yet to define the sub-cellular localisation of the a- 
MSH-R, and subsequent cellular events.
4.9. USE OF PHOTOAFFINITY-MSH PROBES DURING STUDIES 
OF MSH RECEPTORS OF MELANOMA CELLS
The MSH receptor of melanoma cells must be isolated and purified before we can fully 
understand the ligand/MSH-receptor interaction and intracellular signalling pathways. 
Photoaffinity labels attached to a-M SH derivatives and fragments are useful in 
structure/function studies of the MSH-R of both human and murine melanoma. The most 
popular to date is the [Nle4,(125I)Tyr2J)-Phe7,Trp(Naps)9]-a-M SH or Naps-125I-NLDP 
tracer. Naps-125I-NLDP specifically binds and activates the MSH-R. It is useful in the 
identification and purification of the MSH receptor protein(s) from melanoma (Section
4.3.) (152, 158, 166, 167). Unfortunately, affinity estimations of Naps-125I-NLDP for the 
MSH-R were not examined.
The biotinylation of NLDP has proven useful in more ways than the visual monitoring of 
the a-MSH-R. Due to the strong affinity of biotin for avidin (Ka = 1015 M *]) it allowed 
us to partially isolate and purify the MSH receptor from B16 murine melanoma cells in 
combination with a 4-(l-azi-2,2,2-trifluroethyl)benzoic acid (ATB) photoaffinity label Dr. 
George Olivier synthesised the photoaffinity label [125I-Tyr2,Nle4,D-Phe7,ATB-Lysn]-a -  
MSH by attaching ATB to the Lys11 residue of NLDP. Its Kd for a-M SH-R sites on the 
cell surface of B16 mouse melanoma was 3.75xl0-10 M. The addition of the biotin
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molecule to the 125I-ATB-NLDP label, resulted in the irreversible binding of the receptor 
complexes to streptavidin beads. The a-M SH-R was extracted from the plasma 
membrane of B16 melanoma using N^Bi-SS-125!-ATB-NLDP and streptavidin-coated 
magnetic beads (1). The incorporation of the cleavable disulphide bridge between the 
biotin and peptidyl ligand allowed for the elution of the MSH-R-ligand complexes from 
the beads with DTT (1). Although the Bi-SS-125I-ATB-NLDP compound was not tested 
in assays for specific a-M SH-R binding, both it and the 125I-ATB-NLDP probe partially 
purified a doublet band of 43 and 46 kDa (1). This result implies similar binding 
characteristics for the two labels of the a-MSH-R.
The strong affinities of both the Bi-125I-ATB-NLDP and 125I-ATB-NLDP photoaffinity 
labels make them useful tools for the labelling of the a-M SH-R during: 1) auto­
radiography; 2) histological localisation at both the light and electron microscopic levels; 
and 3) extraction and characterisation with SDS-PAGE techniques. The 125I-ATB-NLDP 
and the Bi-125I-NLDP derivatives enabled comparisons with other ATB-NLDP analogues 
such as the Bi-SS-125I-ATB-NLDP compound.
4.10. SITE-SELECTIVE DRUG DELIVERY TO MELANOMA 
CELLS VIA MSH ANALOGUES
4.10.1. INTRODUCTION
Targeting of cytotoxic agents with a-M SH analogues via the melanogenesis pathway is 
not a novel idea (133,194). MSH derivatives have been studied as potential treatments for
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melanoma in the following site-selective drug delivery therapies: 1) radio-therapy; 2) 
cytotoxic MSH related complexes; and 3) melanoma growth retardation.
Treatment with chlorpromazine is an example of creating selective enhancement of the 
cytotoxic effects of gamma-radiation for melanoma via the melanotropin pathway. 
Animals were pre-treated with chlorpromazine (which selectively binds to melanin) in 
order to selectively increase the radio-sensitivity of melanotic melanoma above non­
melanoma cells (20). Pretreated animals showed a marked tumour regression, decreased 
transplant ability of melanoma, and decreased metastasis after irradiation (40). Mishima 
(124) proposed the use of 10B-labelled chlorpromazine in combination with slow neutron 
activation of boron atoms. When compared to gamma-radiation, the 10B isotope capture 
of slow neutrons can be an efficient method of killing cells causing less damage to the 
surrounding tissue (61). The thermal neutron-induced emission of high LET a-particles 
and lithium atoms have a limited travelling range equal to the diameter of individual 
melanoma cells (10-14 pm). ,0B-labelled chlorpromazine depressed the growth rate of 
malignant melanoma in hamsters and pigs (124). Mishima (125) then synthesised hybrid 
compounds of 10B with analogues of the melanin precursor, DOPA. Radio-biological 
studies showed enhanced melanoma cell-killing effect when these compounds were used in 
combination with neutron-radiation. He treated 9 cases of primary and metastic melanoma 
lesions with the DOPA hybrid ^Bj-BPA molecule (125). Unfortunately, large doses of 
10B-BPA (10,000 atoms/cell) are needed for cell death.
Liu et al (115) prepared an a-M SH/T cell receptor antibody conjugate for activation and 
targeting of cytotoxic T lymphocytes to melanoma. Antibodies to the CD3 component of 
the T cell receptor were conjugated to the N-terminal of NLDP. When the NLDP portion 
was bound to the a-M SH-R of melanoma cells, and the CD3 antibody was bound to T 
lymphocytes, significant lysis of mouse (B16-F10) and human (6137 and M1313)
145
melanoma cells occurred (115). Excess a-M SH or CD3 antibody suppressed the cytolytic 
effect of the conjugate. This complex was not examined in vivo.
4.10.2. USE OF MSH-TOXIN CONJUGATES DURING MELANOMA THERAPY
Four types of toxins have been linked to MSH analogues in an effort to target and treat 
melanoma: 1) daunomycin; 2) N-nitrosocaramates; 3) melphalan; and 4) diphtheria toxin.
Daunomycin attached to p-MSH was 3 fold more toxic to cultured Cloudman S91 murine 
melanoma than free daunomycin. It was non-toxic to 3T3 fibroblast cells (102, 186). 
Cytotoxicity occurred via specific interaction with MSH receptors on the cell surface 
(197). There were no studies for its use in vivo. C-teiminal fragments of a-M SH coupled 
to 2-chloroethlnitrosocarbamoyl yielded compounds with marked growth-inhibitory 
actions on melanoma tumours in mice (92). Selective cytotoxicity was not achieved with 
a-M SH fragments containing melphalan either in vitro or in vivo. Although, the a-M SH 
carrier peptide was able to reduce the toxic action of melphalan (an alkylating agent) to 
MSH-R negative cells without affecting its anti-tumour potency (171, 172). Thus, making 
the a-MSH-melphalan conjugate a potentially safer therapeutic agent for melanoma.
Murphy et al (127) constructed a chimeric diphtheria toxin-a—MSH gene with the toxin 
receptor-binding domain replaced by the a-M SH gene sequence. The protein (DAB389- 
MSH) was selectively toxic for human melanoma containing the a-MSH-R. Binding of 
DAB389-MSH to a-MSH-Rs in biopsy specimens of human and mouse metastases was 
confirmed by its ability to inhibit binding of 125I-NLDP. Its binding affinity for the a —
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MSH-R was 3 fold lower than a-M SH in human biopsies, and 5 fold lower than ,25I- 
NLDP in mouse sections (177).
4.10.3. SITE-SELECTIVE DRUG DELIVERY WITH THE MTX-NLDP TOXIN 
TO MELANOMA
In this study the anti-metabolite methotrexate (MTX; 76) was attached to the N-terminus 
of NLDP. Methotrexate is used against a variety of cancers since its toxicity is primarily 
against growing, self-renewing tissues (93). It exerts its cytological action through 
competitive inhibition with dihydrofolate reductase (DHFR) for DHF substrates. The 
conjugate's ability to bind and stimulate cellular activity of a-MSH-Rs found in B16 
melanoma plasma membranes, was compared to other a-M SH derivatives.
The Kd and Ec50 values obtained for the MTX-NLDP conjugate (1.54xl0-9 M and 
2.11xl0-n M) were similar to those observed for NLDP (2.22xl09 M and 2.76xl0-n M). 
Attachment of MTX to NLDP did not compromise the peptides affinity for the a-MSH-R 
or its cellular response. Non-specific binding of the conjugate to the cell surface of B16 
cells was comparable to 125I-NLDP (12% over 8 hours at 0-4sC). The ability of MTX- 
NLDP to raise tyrosinase expression suggests agonistic action of the a-M SH-R, and its 
likely receptor-mediated internalisation (as described for 125I-NLDP at 37fiC). The specific 
binding of MTX-NLDP to the a-M SH-R with a high affinity, low non-specific binding, 
and probable internalisation, are all characteristics of an effective drug compound site- 
selectively delivered to melanoma.
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Unfortunately, an estimated 106 MTX molecules are required for cell death. The low 
receptor numbers of a-M SH on human melanoma cells (400-2,000) and the reduction of 
external a-M SH binding sites after a 1 hour exposure at 37aC, are not conducive to the 
intracellular accumulation of 106 molecules of MTX. There are 3 possible solutions to this 
problem: 1) replace MTX with a more potent toxin; 2) increase the number of MTX 
molecules per peptide and/or MSH-R; 3) up-regulation of the a-M SH-R during treatment 
with MTX-NLDP.
Replacing the MTX molecule with a more cytotoxic compound such as ricin would lower 
the number of internalised toxin molecules necessary for cell death. This approach would 
only be acceptable if non-melanoma binding was minimal.
Modification of NLDP to cany more MTX molecules per peptide is another option. 
Increasing the MTX carrier load might be achieved with a (Bi-MTX)-(Sa)-Bi-NLDP 
compound. This would change the MTX : NLDP ratio from 1 : 1 up to 4 : 1. The (Bi- 
MTX)-(Sa)-Bi-NLDP conjugate would be better suited as a site-specific toxin for 
melanoma since fewer receptor sites would be needed for cytotoxicity. Another means of 
increasing the number of MTX molecules transported by a melanotropin into the 
melanoma cytosol might be the attachment of MTX to a TMV-a-MSH fusion gene 
product (Section 4.7.). In earlier studies, the TMV-a-MSH gene product carried up to 
200 rhodamine molecules per viron and displayed intracellular accumulation (202). By 
replacing MTX for rhodamine molecules, up to 200 MTX molecules might be 
carried/receptor into melanoma cells via the TMV-a-MSH gene product Thus, activation 
of only 5,000 a-MSH-Rs would cause cell death.
There are a number of procedures for the up-regulation of MSH-Rs of melanoma cells. 
MSH receptor up-regulation has been reported with the following treatments: 1) MSH-
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related compounds; 2) retinoic acid; 3) interferons; and 4) ultraviolet light A short 
exposure (hours) of 10* M L-DOPA increased binding of 125I-a-M SH in six human 
melanoma cell lines. Cyclic AMP added to the growth media also increased a-M SH-R 
binding with two optima at 10*11 M and 10* M. Added tyrosine also significantly increased 
specific binding of a-M SH after an hour incubation (72). These results verify earlier 
studies showing a 3 fold increase in the numbers of MSH-Rs after a 48 hour exposure of 
Cloudman mouse melanoma cells to dopa phosphates (123). The effect increased with 
dose. Similar results were observed with Bomirski hamster melanoma cultured for 24-48 
hours in the presence of 2x10* M L-tyrosine. After the L-tyrosine treatment melanoma 
displayed a 3-4 fold increase in their ability to bind 125I-p-MSH (162). It was suggested 
that compounds which activate melanogenesis, up-regulate receptor expression via a 
positive feedback mechanism (72).
Siegrist and Eberle (161) have found that MSH-R regulation varies with the melanoma 
cell line used. They observed a time and dose-dependent up-regulation of MSH-Rs in two 
human lines. The increase of a-M SH binding was maximal after an incubation of 24 hours 
with 10-7 M a-M SH. Up-regulation appeared to be caused by the recruitment of spare 
receptors since it was independent of protein synthesis. Conversely, a 12 hour incubation 
in a-M SH caused MSH-R down-regulation of Cloudman and B16-F1 mouse, and HBL 
human melanoma cells. Alpha-MSH (109 M) caused the disappearance of 85-90% of the 
cell surface MSH-Rs from B16-F1 melanoma cells. This down-regulation may be a 
consequence of receptor internalisation. Our observed decrease in binding of 125I-NLDP 
to B16 plasma membrane receptors after an hour incubation at 31*C is in agreement with 
similar results for B16-F1 cells (161).
Up-regulation of the p-MSH-R (3-4 fold) was evident in Cloudman mouse melanoma cells 
after a 3 hour incubation in 2x10* M retinoic acid (32). Interferon's (a - , (J-, and y-) in
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combination with a-MSH also increased the expression of surface MSH-Rs of a primary 
JB/MS murine melanoma line. There was a 2.5 fold increase in bound ligand after a 4 day 
combined treatment of 2xl0-7 M a-M SH and interferons (94,95).
Exposure of Goudman melanoma cells to UVB radiation increased the binding of 125I- 
MSH 2-10 fold within 24 hours (23). UVB radiation raised IL-1 levels in the melanoma 
cell supernatant Interleukin-1 added to the growth media of melanoma cells increased the 
dose-dependent binding of 125I-p-MSH to its receptor. Birchall et al (18) claimed 
ultraviolet light indirectly up-regulated both cell surface and internal MSH-R activity in 
Goudman melanoma and RHEK human carcinoma cells by stimulating the secretion of 
interleukin-1 by these cells. In this manner, ultraviolet light might trigger an autocrine up- 
regulatory system of MSH-Rs of melanoma cells.
Any, or all, of these pre-treatments may increase the selective delivery of a-MSH-drugs 
to melanoma cells by increasing the number of available a-M SH-Rs at the cell surface.
4.11. INDUCTION OF MELANOMA GROWTH INHIBITION 
WITH MELANOTROPINS
Our studies showed the growth inhibition of B16 mouse melanoma cells by the 
melanotropins a-M SH and NLDP. The response was time, concentration, and cell density 
dependent Pulse doses of 109 M NLDP of 30 minutes per day, had no effect on 
melanoma growth. Melanization, dendritic process development, and cell flattening of B16 
cells occurred after a 4-6 day chronic exposure to both the melanotropins. NLDP indused
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a morphological change and inhibited melanoma proliferation more effectively than a -  
MSH.
NLDP gradually retarded melanoma growth up to 49% after 4-6 days at 109 M. This 
inhibition of cell growth was concentration-dependent as well as time-dependent A clear 
effect was observed at 109-107 M, but was not observed at dilutions of 10-10M or lower. 
Apparently, a higher concentration of peptide is needed to inhibit melanoma growth than 
is needed for tyrosinase stimulation (Ec50 = 3xlOn M). B16 cells had a similar response 
to a-M SH, but inhibition was less pronounced than observed with NLDP. This was 
expected as a-M SH is less potent than NLDP in eliciting melanoma cellular responses 
such as tyrosinase activity and melanin biosynthesis.
Our findings are in agreement with other studies concerning the effects of MSH on mouse 
melanoma (Section 1.6.2.). Pawelek et al (136, 141) observed similar results with 
Cloudman S91 murine melanoma cells. He found MSH extended the doubling time of the 
S91 melanoma cells from 38 to 64 hours, and caused a 25% decrease in cellular DNA. 
After 14 days, there was a 30% growth arrest in the Goudman S91 PS4 sub-clone. The 
growth medium was changed every 3 days. Pawelek suggested MSH inhibited cell 
proliferation only in the G1 or early S phase of the cell cycle. Cells blocked in metaphase 
with colchicine had twice as much DNA than controls when melanoma cells were 
incubated in MSH. Wick (195) also observed growth inhibition of Goudman melanoma 
cells (34%) after 3 days of 5x10-* M MSH, with a cell density of 105 cells/well. He 
observed maximum inhibition after 4 days.
Both Wick and Pawelek (138, 195) found theophylline enhanced the effects of MSH. 
Theophylline inhibits the hydrolysis of cAMP by cyclic nucleotide phosphodiesterase, thus 
raising intracellular cAMP levels. Cyclic-AMP levels are raised when the MSH-R is
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activated. Raised intracellular levels of cAMP have been shown to inhibit cell growth in 
other cell systems. These results suggest the involvement of cAMP during melanoma 
growth inhibition. Other MSH activated intracellular messengers which are thought to 
inhibit melanoma proliferation are cytosolic myoinositol phosphates and protein kinase C 
(28,73,164).
During melanogenesis, tyrosine is catalysed by tyrosinase to form dopa. Dopa also reacts 
with tyrosinase to form dopaquinone. A series of well characterised biosynthetic steps give 
rise to pigmented quinone derivatives, leading to the formation of melanochrome and 
melanin (Section 1.5.3.; 136). Both tyrosine and N-acetyltyrosine have been shown to be 
toxic to melanotic Cloudman S91 cells. The dopa analogue levodopa methyl ester, had 
anti-tumour activity against B16 melanoma in vivo (191). Dopamine was also a potent 
inhibitor of B16 melanoma in vitro and in vivo (193). Melanoma growth retardation by a -  
MSH could be caused by the accumulation of toxic melanogenic products and metabolic 
by-products in the surrounding cellular environments (122, 192). It is suggested that the 
above compounds owe their cytotoxic effect to the generation of super oxide free radicals 
within the cell (194). One component of the pathway, 5,6-dihydroxindole conversion 
factor, is thought to protect the cells from cytotoxic melanin precursors in the absence of 
MSH. Thus, MSH stimulated cells would undergo auto-toxicity during MSH stimulated 
melanogenesis. This explanation is contradictory to our results. We observed growth 
inhibition of B16 melanoma with frequent media changes and optimal culture conditions. 
Although, intracellular accumulation of cytotoxic by-products from melanogenesis were 
not accounted for.
Growth stimulation whs also beenreported as a cellular response to melanotropins 
(Section 1.6.3.). MSH has been shown to encourage metastases in melanoma. It 
stimulated the metastatic capacity of melanoma (118) and; increased melanoma cloning
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and proliferative potentials in agar bilayers (122). It is suggested that this effect is due to 
MSH-induced autocrine growth factors or intracellular messengers (27,118,122,205).
The cellular response of melanoma cells to MSH has been observed to be dependent on 
cell density, substrate, cell line, and metastatic potential. Niles and Makarski (130) found 
that two B16 subclones responded differently to cAMP or MSH depending on their 
metastatic potential. Growth of B16-F1 cells with a low metastatic potential were 
inhibited by MSH and cAMP while cells with a high metastatic potential (B16-F10), were 
not significantly effected. A correlation between the loss of hormonal regulation with 
increased metastatic potential might explain why some cell lines have a high colony- 
forming ability in the presence of MSH.
As cell density increased, Cloudman melanoma cells lost their ability to demonstrate an 
MSH-induced increase in tyrosinase activity (59, 121). Neither theophilline (106 M) or 
dibutyryl cyclic AMP (1(H M), stimulated tyrosinase activity in melanoma cells cultured at 
densities exceeding 6X104 cells/cm2. This loss in hormone responsiveness occurred before 
confluency was reached and was not reversed by exposure of cells to increasing 
concentrations of MSH (59). We observed a different effect with B16 mouse melanoma 
cells. We found growth inhibition (a cellular response to melanotropins) increased at B16 
cell densities exceeding 1.25X105 cells/cm2*. Maximum inhibition occurred more quickly 
when the cells were seeded at higher densities. Malek et al (121) also reported the 
inhibition of melanoma cells by melanotropins, but only when they were plated at very 
high densities. He proposed this reduction of cell growth with an increase in cell density 
was caused by cell contact growth inhibition, and or, the depletion of media nutrients. Our 
results do not agree with the latter explanation as the cell growth media was frequently 
changed. Melanoma cell density may effect MSH induced tyrosinase expression and 
growth inhibition in different ways. It appears that hormonal control over pigment cell
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melanogenesis and cell growth is complicated and controversial at our level of 
understanding.
4.12. CONCLUSION
We report the suitability of a panel of melanotropin probes as tools to localise, diagnose, 
monitor, and characterise and extract the a-MSH-R and its cell cycle. We also present a 
novel MTX-NLDP toxin conjugate which is potentially useful during melanoma therapy. 
Both the probes and toxin operate via an a-M SH carrier which selectively delivers 
compounds (probe or drug) to a-MSH-Rs found on B16 murine melanoma cells in vitro. 
Our studies also report the inhibition of B16 melanoma cell growth by melanotropins. The 
MSH induced growth retardation of melanoma also appears to operate via the MSH 
cellular pathway. This is an additional advantage for the use of melanotropins during 
treatment against melanoma.
Results obtained with the melanotropin probes and MTX-toxin conjugate may be 
summarised as follows:
1) 125I-NLDP specifically binds and activates a-MSH-Rs of B16 melanoma cells in vitro.
It is potentially useful for the localisation, diagnosis, characterisation, and 
monitoring agonist-a-MSH-R complexes during binding and internalisation when 
used in combination with cell fractionation and auto-radiographic studies.
2) CTAF-NLDP specifically binds and activates a-MSH-Rs of B16 melanoma cells in
vitro. It has limited potential for visualising the binding, internalisation, and cellular 
processing of a-MSH-R agonists due to its low affinity for the a-MSH-R.
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3) Bi-NLDP specifically binds and activates a-MSH-Rs of B16 melanoma cells in vitro. It
is a potentially useful probe for the visualisation of the binding and metabolic fate 
of a-M SH-R agonists at both the light and electron microscopic levels.
4) Bi-125I-NLDP specifically binds to a-MSH-Rs of B16 melanoma cells in vitro. It is
suitable for a-M SH-R localisation studies at the cellular (auto-radiography) and 
subcellular (cell fractionation studies, light and electron microscopic studies) 
levels.
5) (Sa)-Bi-125I-NLDP specifically binds to a-MSH-Rs of B16 melanoma cells in vitro. It
allows for the possible augmentation of the probe signal when combined with 
biotinylated labels.
6) (Sa-Au)-Bi-125I-NLDP does not bind selectively to the a-M SH-R of B16 melanoma in
vitro. Thus, it is not suitable for future studies of the a-MSH-R.
7) 125I-ATB-NLDP photoaffinity label specifically binds to the a-M SH-R of B16
melanoma in vitro. It is potentially useful for irreversibly binding and monitoring 
the a-M SH-R during receptor localisation and bioactivation studies.
8) Bi- 125I-ATB-NLDP photoaffinity label specifically binds the a-M SH-R of B16
melanoma in vitro. It led to the development of the Bi-SS-125I-ATB-NLDP 
complex which covalently binds, localises, and allows for the partial purification 
and characterisation of the a-MSH-R when used in combination with streptavidin 
magnetic beads and SDS-PAGE techniques.
9) MTX-NLDP specifically binds and activates a-MSH-Rs of B16 melanoma cells in
vitro. It is potentially useful during site-selective delivery of the MTX toxin to 
melanoma cells.
Melanotropins are potentially useful for treating melanoma. The NLDP analogue of a - 
MSH both inhibits melanoma proliferation and selectively delivers a drug and probes to 
the a-M SH-R of B16 melanoma cells in vitro. Unfortunately, the wide distribution of
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radio-iodinated and tritiated a-M SH and NLDP in rodents implies the need for 
melanotropins to be more selective for melanoma in vivo (175). There needs to be a 
reduction in binding of melanotropins by non-melanoma tissues before MSH can be 
regarded seriously as a targeting agent to melanoma in vivo. This may not be possible 
considering the vast distribution of POMC related receptors within the body (Section
1.2.). Although melanotropins show promise for selective drug delivery to melanoma in 
culture conditions, experiments in vivo are often disappointing (58). Regardless, there 
have been many advancements in this area, and MSH-drug conjugates have been 
successful in selectively targeting and killing (or reducing growth) of melanoma lesions in 
humans (Section 4.10.). Parameters for the future role of melanotropins in the study and 
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APPENDIX




The synthesis of the peptide and its conjugates was performed by Dr. G.W J Olivier, 
therefore the protocol for their synthesis will not be described in full Peptides were 
prepared by solid-phase synthesis using the Fmoc strategy as developed by Atherton and 
Sheppard (6). The peptides were prepared as their carboxyamide forms using the AM- 
linker on Pepsyn K resin. All the amino-acid reagents were used as their pentafluorophenyl 
esters with the exception of serine in which the 3,4-dihydro-4-oxobenzotriazin-3-yl ester 
was employed, and Fmoc-DPhe-OH which was treated with DIC and HOBT to form its 
HOBT active ester in situ. Side chains were protected as follows: Argine, 
methoxytrimethylbenzene-sulphonyl (Mtr); Glutamic acid, t-butoxy (OBut); Histidine, t- 
butoxy-carbonyl (Boc); Lysine, (Boc); Serine, t-butyl (But); Tyrosine (But). A four-fold 
molar excess of reagents was used in all instances.
Deprotection and cleavage was performed using 2% ethanedithiol, 2% anisole and 1% 
water in TFA for 8 hours at room temperature. Peptide was purified using semi- 
preparative HPLC employing a gradient elution of 0.1% TFA in water and 0.1% TFA in
186
acetonitrile : water (70:30) at a flow rate of 3 ml/minute or a preparative HPLC using the 
same solvent system at 10 ml/min. The elutent was continuously monitored by UV 
spectrophotometry at 217 nm. Fractions were collected every 5 minutes in 1.5 or 5 ml 
aliquots and each fraction was tested by analytical scale HPLC. Fractions were bulked 
according to their chromatographic profiles and freeze-dried. Identity was confirmed by 
FAB-MS and for NLDP, co-chromatography with authentic peptide (Sigma Chemical 
Co.). Prior to experiments the peptide was prepared at a stock concentration of 1 mg/ml in 
sterile 0.1 mM HC1 and stored at 42C.
SYNTHESIS OF NLDP CONJUGATES
Peptide conjugates were prepared by the addition of DTAF, MTX (using DIC/HOBT 
activation), or Biotin-NHS in DMF to 300 mg of the protein resin after deprotection of 
the N-terminus. The target peptides were obtained after deprotection and cleavage of the 
peptidyl resin and HPLC purification using the same conditions as for the NLDP-MSH 
analogue. Identity was confirmed by FAB-MS.
Peptides containing the ATB photoaffinity label were prepared according to the procedure 
described by Ahmed et al (1). An HOBT active ester of ATB was preformed with DIC 
and HOBT in DMF (activation time of 45 minutes to 1 hour) and allowed to react with 
purified NLDP or its biotinylated derivative Bi-NLDP, in solution in DMF (100 pi) for 1 
hour. The reaction solution was then diluted 50-fold with water/acetonitrile (19:1, v/v) 
and purified directly by semi-preparative HPLC without UV monitoring. Fractions were 
subsequently analysed for purity by HPLC. The entire procedure was carried out in a dark 
room, under red safety light
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Figure A1.2. HPLC purification of the reaction products from the iodination of NLDP as 
measured by UV adsorption at 217 nm (B) and 277 nm (A). Peaks 1, 2 and 3 are thought 











Figure A1.3. Activity per fraction from the HPLC purification of radio-iodinated NLDP 
from 27 minutes after the injection sample at a flow rate of 1 ml/minute.
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Figure A1.4. Quench curve for 3H20  plotted as the counting efficiency of the beta-counter
vrs the ratio of the cpm/efficiency of the beta-counter.
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APPENDIX 2. EXPERIMENTAL DATA FOR RESULTS
Table A2.3.1. Standard curves for a-M SH radio-immunoassay in bound 125I-a-M SH
(Figure 3.1.)
PMOL a-M SH SERUM NO SERUM SAMPLES
0 3061 3022.5 3010
3.125 3092.5 3059.5 3074
6.25 3100.5 3141 2975.5
12.5 3312.5 3235 2766.5
25 3423 3333.5 3011
50 3527.5 3545.5 2961
100 3698 3734.5 2214
200 3906 3895 2582.5
400 3946.5 3881 2964
2979.5
Table A2.3.2.1.125I-NLDP bound at 37flC with different number of rinses (Figure 3.2.1.)
HRS RINSE 1 RINSE 2 RINSE 3 RINSE 4
0.02 8964.2 4418 3403.1 3054.4
0.5 21214 16268 12910 17260
1 22620 19235 17801 17841
2 16815 16361 14145 12909
4 18153 11483 10038 9031.2
Table A2.3.2.2.125I-NLDP bound at 37°C in different buffers; total and non-specific to 
the wells (Figure 3.2.2.)
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HRS RPMI+BSA RPMI PBS+BSA PBS
0.02 401.5 316.13 610.25 429.25
0.5 1456.8 1462.3 1346.8 1432
1 1732.4 1794 1190.5 1005
2 1244 1341.6 1022.7 1049.3
4 1640.4 1159.2 1155.2 626.35
NS 1 112.4 59 348.8 72.1
NS 2 137.5 125.9 221.6 159.7
Table A2.3.2.3.125I-NLDP bound at 372C in RPMI or MEM media; total, non-specific
to the cells, and specific (Figure 3.2.3.)
HRS RHOT RHC RSP MHOT MHC MSP
0.02 740.08 382.7 357.38 983.6 443.05 540.55
0.5 1943.8 551.45 1392.4 1887.8 698.83 1188.9
1 2206.2 574.87 1631.4 2270.1 757.7 1512.4
2 1695.7 596.05 1099.7 1816.8 669.62 1147.2
4 1393.8 769.37 624.4 1862 724.2 1137.8
Table A2.3.2.4.125I-NLDP bound at 37®C with and without, 0.3 mM 1,10-
phenanthroline (Figure 3.2.4.)






Table A2.3.2.5.125I-NLDP bound at total, non-specific and acid stripped (Figure
193
3.2.5.)
HRS HOT HC ACID
0.02 1793.5 469.58 85.65
0.5 20635 608.1 3268.9
1 36953 912.85 9612.7
2 27657 699.18 9182.7
4 28684 1126.5 7539.2
Table A2.3.2.6.125I-NLDP bound at lS^C; total, non-specific, specific, and acid stripped
(Figure 3.2.6.)
HRS HOT HC SP ACID
0.02 591.75 101.65 490.1 57.225
0.5 3092.2 179 2913.2 252.37
1 5350.7 231.7 5119 517
2 9902.2 303.07 9599.2 1804.4
4 13103 335.5 12767 2666.4
6 15274 307.87 14967 3969.2
29 21936 535.22 21401 9239
Table 2A.3.2.7. ,25I-NLDP bound at 42C; total, non-specific and acid stripped (Figure
3.2.7.)
HRS HOT HC ACID
0.02 420 333 89
0.5 741 270 86
1 1100 255 112
2 1754 291 154
4 2538 408 194
6 3274 398 202
25 5293 248 384
194
Table A2.3.2.8.125I-NLDP bound at 42C, 0.5 and 2 hours vrs cell density; total and non­
specific (Figures 3.2.8. and 3.2.9.)
cyw 0.5 HR HOT 0.5 HR HC 2 HR HOT 2HRHC
5 00000 2252.4 313.92 4610.5 478.12
400000 1602 436.7 3242 417.62
300000 1011 299 2160 324.92
200000 822.18 301.52 1349 457.22
100000 401.62 315.92 585.13 294.45
Table A2.3.2.9.125I-NLDP bound at 4®C with and without, 0.3 mM 1,10-phenanthroline
(Figure 3.2.10.)







Table A2.3.2.10.125I-NLDP bound at 42C with and without, various concentrations of
collagenase inhibitor (Figure 3.2.11.)
HRS 10-5 MOLE 10-6 MOLE 10-7 MOLE n o  a
1 3377 3360.5 4321.1 4408.3
2 5139.7 5613.5 4620.4 6284.3
4 7174.9 7312.9 6783.3 6728.7
8 6728.3 7404.7 7284.8 7966.5
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Table A2.3.2.11 .125I-NLDP bound at 4®C at different tracer concentrations; total and 
non-specific (Figure 3.2.12)
HRS H 1.08 HC 1.08 H0.27 HC 0.27
0.02 245.75 164.75 117.25 98.25
0.5 656.25 287 198.5 111.5
1 1032.2 411.25 274 101.5
2 1460 322.75 382.25 107.25
4 1981.5 340.75 506.75 130
6 2423 438.5 721.75 136
22 3547.7 453.75 1118.7 131.25
Table A2.3.2.12.125I-NLDP specifically bound at 42C at different tracer concentrations 
(Figure 3.2.13.)
HRS SP 0.59 SP 0.838 SP 0.27 SP 1.08
0.02 238.58 77 19 81
0.5 1678.2 471 87 369.25
1 2704.5 844 172.5 620.95
2 5148.8 1463 275 1137.3
4 6815.1 2130 376.75 1640.8
6 8265.2 2886 585.75 1984.5
8 10159 * * *
14 11779 * * *
24 * 5045 987.45 3093.9
Table A2.3.2.13. Binding isotherms of 125I-NLDP; total bound and non-specific (Table 
3.2.1.). Isotherm 2* is plotted in Figures 3.2.14. and 3.2.15.





























































Table A2.3.2.14. Binding of tracer in competition with dilution series of unlabelled


















-7 688 -7 628.75 -7 663.45
-8 1261.1 -8 1507.3 -8 1493.3
-8.301 1810.5 -8.301 2104.2 -8.301 2196.6
-8699 3179.9 -8.699 3743.8 -8.699 3503
-9 4678.5 -9 5789.9 -9 5848.5
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-9.301 6712.5 -9.301 7593.1 -9.301 7667.9
-9.4559 7937.4 -9.4559 8695.8 -9.699 10507
-9.699 9564.4 -9.699 10400 -10 12195
-10 10517 -10 11468 -10.301 12869
-10.301 11398 -10.301 12084 -10.699 13437
-10.699 11989 -10.699 12276 -11 13473
-11 12138 -11 12374 0 12688
NLDP 4 CPM NLDP 5 CPM NLDP 6 CPM
LOG TRACER = LOG MOLE TRACER = LOG TRACER=
MOLE 0.120 nM 0.124 nM MOLE 0.655 nM
-7 736.38 -6 1309.1 -7 1267.8
-8 699.12 -8 1369.9 -7.301 1496.9
-8.4559 695.12 -9 4118.7 -8 2907.9
-9 793.8 -10 9255.3 -8.301 4902.7
-9.301 1373.1 -11 8373.9 -8.6021 7066.9
-9.4559 2170.5 0 10386 -9 11401
-9.699 3323 -9.1249 12360
-10 3756.3 -10 24876
33-10.456 4001.9 -10.301 27877
-11 4281.1 -11 29378
-12 4274.5 -12 31245
0 4229.7 0 30468
NLDP 7 CPM NLDP 8 CPM NLDP 9 CPM
LOG TRACER = LOG MOLE TRACER = LOG TRACER =
MOLE 0.134 nM 0.136 nM MOLE 0.136 nM
-6 470.3 -7 609.85 -7 632.33
-7 534.2 -8 1555.2 -8 1510.4
-8 988.63 -9 7709.7 -9 7167
-8.301 1360 -10 15041 -10 14063
-9 3531.8 -11 17172 -11 15914





NLDP 10 CPM a-M SH 1 CPM a-M SH 2 CPM
LOG TRACER = LOG MOLE TRACER = LOG TRACER =
MOLE 0.139 nM 0.142 nM MOLE 0.655 nM
-6 404.52 -6 425.02 -5.301 1089.9
-7 403.12 -7 565.8 -6 1470.9
-8 812.13 -8 1391.3 -7 3003.6
-9 4086.8 -8.301 1867.1 -7.301 4328.9
-10 8555.5 -8.699 2846.5 -8 10399
-10.301 8784.7 -9 3288.8 -8.301 15808
-11 9841.6 -9.301 3774.4 -8.6021 17890
-12 9563.7 -9.699 4201.6 -9 22259
-10 4386.9 -9.1249 25137
-11 4576.5 -10 29047
-12 4229.3 -10.301 30259
0 4125.2 -11.301 31584
a-M SH 3 CPM a-M SH 4 CPM CTAF1 CPM
LOG TRACER = LOG MOLE TRACER = LOG TRACER =
MOLE 0.125 nM 1.73 nM MOLE 0.128 nM
-7 1157.5 -7 5553.2 -5 507.3
-7.4559 1812.9 -7.301 9457.3 -6 597.82
-8 3598.3 -8 22237 -7 1295.5
-8.301 5817.6 -8.301 30879 -7.301 1978.3
-8.4559 6290.9 -8.6021 31476 -7.699 3537.4
-8.699 7552 -9 39338 -8 5614.3
-9 10234 -9.1249 38961 -8.301 8046.3
-9.301 12286 -10 41316 -8.699 11090
-9.4559 11869 -12 45235 -9 12796
-9.699 12708 0 43390 -9.4559 13752
-10 13040 -10 13865
-11 13664 -11 13329
CTAF2 CPM CTAF3 CPM MTX1 CPM
LOG TRACER = LOG MOLE TRACER = LOG TRACER =
MOLE 0.152 nM 1.47 nM MOLE 0.126 nM
-6 555.3 -4.301 3491.9 -6 404.65
-7 1832.1 -5.301 3801.2 -7 535.58
200
-8 7527.2 -6.301 9073.7 -7.301 560
-9 10785 -7.301 17902 -8 844.5
-10 10334 -8.301 18098 -8.301 1129.8
-11 9837.3 -9.301 21935 -9 3150.3
-10.301 23001 -9.301 4918.6
-11.301 26337 -10 8790.9
-12.301 22527 -11 11087
0 24674 -12 10937
0 11076
MTX2 CPM MTX 3 CPM BI1 CPM
LOG TRACER as LOG MOLE TRACER = LOG TRACER =
MOLE 0.142 nM 0.142 nM MOLE 0.120 nM
-6 585.35 -6 490.92 -7 340.25
-7 568.68 -7 542.9 -8 428.67
-8 809.38 -8 1012.7 -8.4559 544.37
-9 2208.2 -9 2908.6 -9 864.3








B I2 CPM BI3 CPM B I4 CPM
LOG TRACER = LOG MOLE TRACER = LOG TRACER =
MOLE 0.124 nM 0.108 nM MOLE 0.116 nM
-6 1309.3 -7 815.73 -7 1244.9
-7 1346.3 -8 1029.1 -8 1125.9
-8 1522.3 -8.301 1036.6 -8.301 3256.6
-9 3014.7 -8.4559 1006.2 -8.699 3289.8
-10 7300.3 -8.699 1227.4 -9 1292.5
-11 9117 -9 1102 -9.301 1804.4
-12 8188.2 -9.301 1263.9 -9.699 1614
-13 8560.5 -9.4559 1173.6 -10 2268
0 9399 -9.699 1662 -10.456 3311.3
-10 1893.8 -11 3570.6
201
-10.456 2471.9 -12 2654.2
-11 2369.6 0 2694.9
0 2270
B I5 CPM Bn l CPM B n 2 CPM
LOG TRACER = LOG MOLE TRACER = LOG TRACER =
MOLE 0.123 nM 0.134 nM MOLE 0.473 nM
-7 280.27 -7 431.75 -7 1249.4
-8 347.52 -8 574.77 -8 1277.2
-8.301 339.77 -8.301 723.52 -8.4559 1643.8
-8.699 521.1 -8.699 * -9 2393.8
-9 642.88 -9 1340.8 -9.4559 3326
-9.301 573.38 -9.301 1952.1 -10 4140.7
-9.699 588.52 -9.699 ♦ -10.456 4078.1
-10 808.23 -10 3021.6 -11 4370.3
-10.456 1135.2 -10.301 3253.7 -11.456 4389.4
-11 1365.2 -10.699 3729.4 -12 4490.3
-12 1331.8 -11 3736.7 -13 4435.7
0 1432 -12 3520.3 0 4401.9
BH 3 CPM BHATB 1 CPM BHATB2 CPM
LOG TRACER = LOG MOLE TRACER = LOG TRACER=
MOLE 0.137 nM 0.143 nM MOLE 0.337 nM
-7 1337.7 -4 9740 -6 11270
-8 1694.7 -5 9996 -7 10995
-9 2730 -6 11547 -8 12378
-10 4331.4 -7 11910 -9 18180
-11 4726.8 -8 15050 -10 33360
-12 4644.2 -9 25062 -11 41985
-10 48900 -12 51317
-12 56740
0 58207
IATB 1 CPM IATB 2 CPM IATB 3 CPM
LOG TRACER = LOG MOLE TRACER = LOG TRACER =
MOLE 0.137 nM 0.126 nM MOLE 0.070 nM
-6 2039.7 -6 1602.3 -7 1590.5
-7 2350.9 -7 2287 -8 1862.2
202
-7.4559 2547.3 -7.4559 2311.5 -8.4559 1954.4
-8.301 3149 -8 2469 -9 2101.8
-8.699 3613.3 -8.4559 2682.1 -9.4559 2270.6
-9 3935.8 -9 3628.2 -10 2178.1
-9.301 4201.4 -9.4559 4197.8 -10.456 2546
-9.699 4496.1 -10 5214.6 -11 2500.3
-10 4569.8 -10.456 5441 -11.456 2621
-11 5100.7 -11 5602.3 -12 2507
-12 4677.3 -12 5463.9 -13 2494.6





















-6 1387.2 -7 1444 -7 1633.2
-7 1826.8 -8 1678.2 -8 1803.1
-8 2145.8 -8.301 2158.1 -9 2191.7
-8.301 2441.1 -8.699 2520.4 -10 2933.2
-8.699 2826.3 -9 3136.6 -11 3092.7
-9 3396.6 -9.301 3837.9 -12 2808.5
-9.301 4439.3 -9.699 5302.1
-9.699 5123.8 -10 5596.1
-10 5599.6 -10.301 6128.7
-10.301 6071.7 -10.699 6246.3
-11 6127.6 -11 6164.1





















Table A2.3.3.1. Tyrosinase assay with for 24 hours using 5x10s and 10s cells/well (Figure
3.3.1.)








Table A2.3.3.2. Tyrosinase assay for 24 hours using 10s, 2.5x10s and 5x10s cells/well
(Figure 3.3.2.)
LOG MOLE NLDP DPM 10s C/W DPM 2.5x10s C/W DPM 5x10s C/W
-8 100280 99735 71459
-9 113180 96353 *
-10 106480 97204 77079
-11 101400 120500 *
-12 90677 105350 78163
0 83469 104340 79708
Table A2.3.3.3. Tyrosinase assay for different times at different cell densities (Figure
204
LOG MOLE NLDP DPM 105 C/W 
27 HRS
DPM 3X104 C/W 
48 HRS
DPM 3X104 C/W 
72 HRS
-6 * * 91287
-7 93542 193560 113400
-8 88229 200510 116010
-9 94548 208790 124630
-10 93750 196790 114320
-10.456 83814 182740 ♦
-11 87533 190720 95100
-11.456 84835 184600 *
-12 82447 195480 68496
-13 77338 195050 76458
-14 81533 182470 84716
-15 100850 174340 77310
-16 ♦ * 70746
-17 * * *
0 86413 183690 68893
Table A2.3.3.4. Tyrosinase assays for all analogues tested Assay 1 of each analogue is











-6 91496 -6 130690 -7 105640
-7 94542 -7 129750 -8 149240
-8 113720 -8 133660 -8.301 143250
-9 128090 -9 142520 -8.699 145650
-10 114910 -10 125360 -9 158930
-11 80928 -10.301 123260 -9.031 153250
-12 60308 -11 103570 -9.699 146890
-13 64112 -11.301 118400 -10 144540
-14 68846 -12 110660 -10.301 146690
-15 68592 -13 104800 -10.699 131520
-16 64778 -14 98529 -11 166410












-6 200730 -9 110430 -6 91287
-7 210620 -10 115380 -7 113400
-8 206380 -10.222 126950 -8 116010
-9 208660 -10.456 108030 -9 124630
-10 208510 -10.699 104620 -10 114320
-11 195920 -11 90168 -11 95100
-12 177990 -11.222 53596 -12 68496
-13 174540 -11.456 66588 -13 76458
0 184680 -11.699 76474 -14 84716
-12 85605 -15 77310












-8 81810 -7 111390 -8 69423
-9 83345 -8 98071 -9 73371
-9.4559 83158 -8.4559 108720 -9.301 77673
-10 84245 -9 105020 -9.699 66161
-10.301 78270 -9.301 91990
otH1 70740
-10.456 73785 -9.699 91449 -10.301 71787
-10.699 72022 -10 94197 -10.456 55137
-11 57778 -10.456 95992 -10.699 48782
-11.301 52214 -11 77750 -11 41838
-11.699 52834 -12 55736 -11.456 37296
-12 46803 -13 52640 -12 30600




DPM a-M SH 1
LOG
MOLE




-8 112150 -7 72614 -6 91287
-8.4559 116890 -8 73969 -7 11340
-9 118630 -8.4559 72267 -8 116010
-9.301 115490 -9 60806 -9 124630
206
-9.699 113410 -9.301 60837 -10 114320
-10 113680 -9.699 50094 -11 95100
-10.301 114380 -10 48628 -12 68496
-10.699 10840 -10.301 42872 -13 76458
-11 101630 -10.699 38427 -14 84716
-11.456 85537 -11 37886 -15 77310
-12 84653 -12 36831 -16 70746
0 84425 0 35519 0 68893
a-M SH  3
LOG
MOLE







-6 111930 -6 75338 -7 131840
-7 140200 -7 95591 -8 137700
-8 141420 -8 98358 -8.4559 15378
-9 141800 -9 88739 -9 132350
-10 119990 -10 69577 -10 115820
-11 91919 -11 57624 -11 78898
-12 94079 -12 54196
-13 104860 -13 57312













-6 203400 -6 143590 -6 127600
-7 212610 -7 166550 -7 125970
-7.4559 209870 -8 161920 -7.4559 144620
-8 215830 -9 131400 -8 137940
-8.4559 211240 -10 125030 -8.4559 134680
-9 203390 -11 125370 -9 119380
-9.455 217320 -12 115560 -9.4559 132510
-10 208610 -13 119820 -10 136270
-10.456 202700 -14 125970 -10.456 142750
-11 207790 0 114920 -11 125960
-12 192890 -12 139100












-8 87802 -6 195470 -6 .186550
-9 88915 -7 205380 -7 203210
-9.4559 88217 -8 202200 -8 201450
-10 83548 -9 205390 -9 204390
-10.301 76584 -10 199000 -10 189230
-10.456 70673 -11 187240 -11 180290
-10.699 68147 -12 175740 -12 156000
-11 63702 -13 170040 -13 176030











-7 184090 -6 153420
-8 188680 -7 162300
-8.4559 200930 -8 144390
-9 209660 -9 155350
-9.301 199260 -10 143770
-9.699 188550 -11 131240
-10 193040 -12 134760
-10.456 185080 -13 146600
-11 166390 -14 111430
-12 159790 0 114920
-13 162900
0 166700
Table A2.3.4.1. Effect of chronic lO9 M NLDP and a-M SH on cell growth (Figure
3.4.2.)
HRS NO NLDP NLDP MSH
cyw cyw cyw
208
0 50000 50000 50000
22 115000 112000 111000
47 392000 296000 310000
70 797000 664000 760000
94 1430000 900000 1080000
115 1190000 318000 844000
142 1370000 810000 920000








0 5X104 5X104 5X104
24 83750 72250 75000
48 214500 215000 234750
72 496000 351500 535000
97 1051000 653500 1016500
Table A2.3.4.3. Effect of chronic 10-9 M NLDP on cell growth at different cell densities
(Figures 3.4.3-3.4.9.)





































































-7 70000 213000 450000 651000 619000 773000
-8 70000 213750 409000 585000 830000 867000
-9 70000 207500 404500 657000 825000 784000
-11 70000 222750 428000 733500 926000 1252000
0 70000 204750 448500 569250 1186000 1307000
211
